

FOIA MARKER

This is not a textual record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

Collection/Record Group: Clinton Presidential Records

Subgroup/Office of Origin: National AIDS Policy Office

Series/Staff Member:

Subseries:

OA/ID Number: 19423

FolderID:

Folder Title:

Department of Health and Human Services (HHS)-International Health [2]

Stack:

S

Row:

66

Section:

7

Shelf:

7

Position:

1



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Memorandum


Date December 22, 1995

From Director
Office of International and Refugee Health

Subject Follow-up on International Health Representatives Meeting -
FDA Home Page

To PHS International Health Representatives

At the December PHS International Health Representatives Meeting, during discussion of the Gore-Chernomyrdin Home Page, Walter Batts of FDA advised that there is an FDA Home Page. This includes international alerts, FDA news and a broad range of information on FDA programs. A copy of material, provided by Walter, on the FDA Home Page is attached. You may wish to share this with colleagues who would be interested.


Linda A. Vogel

Attachment

The Internet address for FDA home page where import program information is located :

<http://www.fda.gov>

At the FDA home page, tab to the icon labeled INSPECTION & IMPORT and click. The first page shows:

```

:-----:
:                                     FDA/ORA Home Page                                     :
:                                                                                         :
:      U.S. FOOD AND DRUG ADMINISTRATION      :
:      FDA OFFICE OF REGULATORY AFFAIRS      :
:                                                                                         :
:-----:
: Information provided by the server :
:                                     :
: Overview of ORA operation          :
: Access to Import Program          :
:-----:
:                                     :
:DISCLAIMER [comment]    [FDA home page] :
:-----:

```

Tab to "Import program" and click. The next page shows:

[illegible]

TO ACCESS IMPORT ALERTS

Tab to "Current Import Alerts" and click. This page shows:

```
:-----:
:                                     ORA IMPORT ALERTS                                     :
:                                     :
:               U.S. FOOD AND DRUG ADMINISTRATION               :
:               ORA IMPORT SYSTEM                                :
:-----:
: View Import Alerts by                                         :
:   option 1: COUNTRY                                           :
:   option 2: INDUSTRY                                           :
:   option 3: IMPORT ALERTS BY NUMBER                           :
:   option 4: WORD SEARCH                                        :
:-----:
:[comment]   [FDA home page]                                   :
:-----:
```

Tab to COUNTRY and click to see Import Alerts listed according to country (first page shown as example):

```
:-----:
:               NUMBER OF ALERTS BY COUNTRY (p1 of 4):       :
:   NUMBER OF ALERTS BY COUNTRY                               :
:-----:
* CNTRY: ALL COUNTRIES                2                       :
* CNTRY: ARGENTINA                    2                       :
* CNTRY: AUSTRIA                      2                       :
* CNTRY: BAHAMAS                     1                       :
* CNTRY: BANGLADESH                  3                       :
* CNTRY: BELGIUM                     1                       :
* CNTRY: BOLIVIA                     1                       :
* CNTRY: BRAZIL                      6                       :
* CNTRY: BRITISH VIRGIN ISLANDS      1                       :
* CNTRY: BURMA                       1                       :
* CNTRY: CANADA                      24                      :
* CNTRY: CHILE                       5                       :
* CNTRY: CHINA                       21                      :
:-----:
```

Tab to the Country of interest and click to see the Import Alerts for that country.

Tab to INDUSTRY and click to see Import Alerts listed according to industry (first page shown as example):

```

:-----:
:                IMPORT ALERT CATEGORY (p1 of 2):
:
:                U.S. FOOD AND DRUG ADMINISTRATION
:                ORA IMPORT SYSTEM
:-----:
: Import Alerts
:
: This is a list of Alert categories.
:
* FOODS
* COLOR ADDITIVES
* CONVEYANCES
* COSMETICS
* VITAMINS
* HUMAN DRUG
* BIOLOGICS
* ANIMAL DRUGS & FEEDS
* MEDICAL DEVICES & DIAGNOSTIC PRODUCTS
* RAD HEALTH
* MISCELLANEOUS
:
:-----:
: [comment] [FDA home page]
:-----:

```

Tab to the category and click to see Import Alerts for that category.

Tab to IMPORT ALERTS BY NUMBER and click to see Import Alerts listed by number (first page shown as an example):

```

:-----:
:                                     (p1 of 52)
:
Alert    Revised    Title/Description
02-01    03/31/88    AUTOMATIC DETENTION OF WHITE OR BROWN
                        BASMATI RICE FROM INDIA
:
02-02    04/27/92    AUTO DET OF RICE PRODUCTS FROM THAILAND &
                        RICE FLOUR (POWDER) FROM HONG KONG (REV)
:
02-03    02/08/90    AUTOMATIC DETENTION OF RICE BASED
                        PRODUCTS FROM THE PHILIPPINES
:
02-06    05/23/91    AUTOMATIC DETENTION OF PSYLLIUM HUSK FROM
                        MAYUR INDUSTRIES AND NAVDEEP INDUSTRIES
:-----:

```

Tab to WORD SEARCH and click to search Import Alerts database by key word. The page shows:

:-----:
FDA WWW Search System

FDA Import Alert Search System

This system provides the capability to search HTML documents located on the FDA WWW main server. It is important to note that this search utility currently searches all FDA public information loaded on the FDA WWW server by default. If the user wishes to only search IMPORT ALERT documents they must change the Limit search to a subtree of document hierarchy to IMPORT ALERT. To limit the search click on the box and a list of possible values are displayed. Place your cursor on IMPORT ALERT and click on this value to limit the search to IMPORT ALERT documents.

[Search] Back

If your browser does not support forms, you can use the system's ALTERNATE SEARCH ENGINE for text-only viewers.

Click on [SEARCH], which leads to the next page:

FDA INDEXING GATEWAY

Type in the keyword, or provide several keywords connected with "and" and "or". Examples: "picture and binary".

You can restrict searches to documents that have changed during the last n days (leave the other fields empty to get all documents changed during that time):

Number of days: _____

Turn on use of thesaurus to extend a search to all synonyms of a term, turn on substring matching to extend searches to words which contain the given term as a substring:

☐ Use thesaurus ☐ Substring matching

Limits search to a subtree of the document hierarchy:
[Search in all documents]

Start search: Ok

NOTE: At [SEARCH IN ALL DOCUMENTS], pull down the window and select IMPORT ALERTS ONLY to limit the search.

If you tab to ALTERNATE SEARCH ENGINE instead, then the next page is:

FDA INDEXING GATEWAY

This is a gateway to the ICE indexing software. By supplying keywords and setting special options, you can do a free text search on this World Wide Web archive.

Type in a search query in your browsers search dialog. Here is a short description of the syntax: Enter the keyword, or provide several keywords connected with "and" and "or". Example: "picture and binary". Ed (1) style pattern matching is also possible.

Turn on use of thesaurus to extend a search to all synonyms of a term, turn on fault tolerant searches to extend searches to words which are "similar" to the given term. The thesaurus can be turned on by adding "-T" after the keyword(s). By adding -S after the keywords, a search not only matches whole words but also substrings. Adding -D followed by a number restricts the search to those files that were updated in the last n days.

You can provide an optional path context which limits searches to certain subtrees of the document hierarchy. The context is separated with a "@" and added to the end of the query.

Here's a full blown example:

.ender.* or animation -T @ /icib/it

will retrieve files which

- * have a URL path starting with /icib/it
- * contain the word animation or a related term
- * contain a word starting with any letter followed by the string "ender", followed by an arbitrary number of letters, or a term related to any word in the thesaurus which matches this expression. Ok, normally you won't need all these features at once.

Tab to "Import Detention reports" and click; the page shows:

Tab to "Introduction to Import Detention" and click to review the format and identifiers of the import detention data provided in the reports.

```

:-----:
:                                     ORA IMPORT DETENTION      :
:                                     :                          :
:                                     :                          :
:      U.S. FOOD AND DRUG ADMINISTRATION      :
:      IMPORT DETENTION REPORTS                :
:-----:
: View Import Detention by                      :
: :                                              :
: *  option 1: COUNTRY                        :
: *  option 2: INDUSTRY                      :
: *  option 3: WORD SEARCH                    :
: :                                              :
:-----:
: [comment]    [FDA home page]                 :
:-----:

```


Tab to COUNTRY and click to see Import Detentions listed according to country:

```
:-----:
:                                     :
:                               ORA IMPORT DETENTION (p1 of 2) :
:                                     :
:       U.S. FOOD AND DRUG ADMINISTRATION :
:       IMPORT DETENTION REPORTS :
:                                     :
:-----:
: View Countries for :
: :
: * SEPTEMBER 1995 :
: * AUGUST 1995 :
: * JULY 1995 :
: * JUNE 1995 :
: * MAY 1995 :
: * APRIL 1995 :
: * MARCH 1995 :
: * FEBRUARY 1995 :
: * JANUARY 1995 :
: * DECEMBER 1994 :
: * WORD SEARCH :
:-----:
: [comment] [FDA home page] :
:-----:
```

Tab to INDUSTRY and click to see Import Detentions listed according to industry:

```
:-----:
:                                     :
:                               ORA IMPORT DETENTION :
:                                     :
:       U.S. FOOD AND DRUG ADMINISTRATION :
:       IMPORT DETENTION REPORTS :
:                                     :
:-----:
: View industries for :
: :
: * SEPTEMBER 1995 :
: * AUGUST 1995 :
: * JULY 1995 :
: * JUNE 1995 :
: * MAY 1995 :
: * APRIL 1995 :
: * MARCH 1995 :
: * FEBRUARY 1995 :
: * JANUARY 1995 :
: * DECEMBER 1994 :
: * WORD SEARCH :
:-----:
: [comment] [FDA home page] :
:-----:
```

Tab to WORD SEARCH and click to search the Import Alerts database by key word as described above.



Overview

Welcome to Internet FDA

Your Electronic Source of Information about the U.S. Food and Drug Administration



FDA News



Animal Drugs



Biologics



Cosmetics



Human Drugs



Foods



Toxicology



Medical Devices and Radiological Health



Inspections and Imports



DISCLAIMER

SEARCH

COMMENTS



US FDA/CFSAN; 200 C Street SW.; Washington, DC 20204 USA

Center for Food Safety & Applied Nutrition

[FDA Overview](#), [FDA Milestones](#) & details about [CFSAN](#)
[Other regulatory agencies with responsibilities for foods](#)

[Biotechnology or Biological & Plant Toxin Info](#)

[Consumer Advice and Material for Educators](#)

[Cosmetics](#) **New!**

[Food Additives, Pesticides and Chemical Contaminants](#)

[Foodborne Illness and Bad Bug Book](#) (Foodborne Pathogenic Microorganisms and Natural Toxins)

[Food Labeling and Nutrition information](#)

[Imports, Exports, Inspections and HACCP](#)

[Press Releases and Other News](#) **UPDATED**

[Seafood Information, Seafood Encyclopedia and Fish Images](#) **UPDATED**

[Video Satellite Teleconferences](#)

[Request](#): How to make a Freedom of Information Act Request to FDA; To Report [Problems](#), to get Information on [CFSAN Advisory Committees](#), to call [The Seafood Hotline](#) by FDA/CFSAN (Toll Free), and to get Written Guides [For Consumers](#); for Industry and Importers of Food, get The Food Labeling Guide; How to obtain all of the written FDA [Regulations](#)

E-Mail and Phone Numbers for CFSAN, FDA & HHS

[Internet E-Mail addresses](#) of all of CFSAN (plaintext)

[Search HHS Phone book](#) (Search Includes all of FDA)

[Get entire FDA Phone book](#) (text file 810Kbytes)

-Known to Break Some PC Browsers--use ZIP file below-

[ZIP file of entire FDA Phone Book](#) (Use PKUNZIP to expand)

Other FDA INTERNET sites publically available are:

[FDA BBS System](#)

[FDA WWW Server](#)

[FDA/CDER Gopher Center for Drugs and Experimental Research](#)

[FDA/CFSAN Anonymous FTP file server](#)

[FDA/CVM Web Server Center for Veterinary Medicine](#)

[FDA/NCTR Gopher National Center for Toxicological Research](#)

[Parklawn Computer Center MVS Gopher](#)

[Parklawn Computer Center WWW Server](#)

[Go back to the Home Page for this Server](#)

Selected Non-FDA Sources of Food Information:

Other Sources of Food and Nutrition Information **UPDATED**

disclaimer

Last updated on 11/26/95 by LRD

Biotechnology

- ☐ [Backgrounder on Biotechnology](#)
- ☐ [Background on Emerging Technologies](#)
- ☐ [First Biotech Tomato](#)
- ☐ [Industry Procedures](#)
- ☐ [Questions and Answers on Biotechnology](#)
- ☐ [Listing of final consultations under FDA's Biotechnology Policy](#)

Go BACK to the CFSAN/FDA food and consumer information page

last updated 7/15/95 by LRD

US FDA/Center for Food Safety & Applied Nutrition

Consumer Advice

A Health Alert for Hispanic Pregnant Women
Best Bet for Babies Breast-Feeding

Consumer Advice about Mercury in Fish, Pesticides in Food, Lead in Food, and
Handling Eggs Safely, and Vegetarian Diets

Food and Drug Interactions
Protect children from iron poisoning

Food: Safe Handling and Preparation of Ground Meat
If you eat Raw Oysters you need to know
Can your Kitchen Pass the The Food Safety Test

Foodborne Illness General Information on E.coli

Food Safety Advice for Persons with AIDS

Important Health Information for People with
Liver Disease, Diabetes Mellitus, Gastrointestinal Disorders, or Immune Disorders

E-Mail Questions about Consumer Advice contents to oco@fdacf.ssw.dhhs.gov
Go BACK to the CFSAN/FDA food and consumer information page

(Last updated 9/26/95 by lrd)

U.S. Food and Drug Administration

FOOD RISKS: PERCEPTION VS. REALITY

A Program to Promote Food Risk Awareness and Understanding

This program presents important food safety information to high school students and encourages critical thinking skills!

Prepared by the U.S. Food and Drug Administration and

The International Food Information Council Foundation, 1993

CONTENTS

- Text Correlation Chart
- Lesson 1: Food Safety: Everyone's Responsibility
- Lesson 2: Should We Risk It?
- Lesson 3: What is the Sum of Food Additives?
- Lesson 4: Is Food Poisoning Really Such a Big Deal?
- Lesson 5: Food Poisoning: What's My Best Defense?
- Lesson 6: What Can I Do? How Can I Remember?
- Lesson 7: Food Labels: How Can They Help?
- Lesson 8: How Can I Sort This All Out?
- Check-Out Quiz
- Resource List

PROGRAM OBJECTIVES

1. To provide information that will help students to

- analyze media reports about food safety and determine the reliability of the information and the risk to them or their family.
- commit to memory the information needed to evaluate risk potential and take appropriate steps to avoid or to minimize risk.

2. To motivate students to keep informed about food safety issues and to take the steps necessary to avoid or minimize food safety risks.

Printed copies of this complete booklet may be purchased from the International Food Information Council Foundation.

Go BACK to the CFSAN/FDA food and consumer information page

Hypertext by dms, 10/95

COSMETICS

Cosmetic Safety, FDA Requirements and Programs

[Cosmetic Safety and FDA Authority](#)
[Animal Testing](#)
[Color Additives](#)
[Cosmeceutical](#)
[Inspection of Cosmetics and Imports](#)
[Over the Counter \(OTC\) Drugs versus Cosmetics](#)
[Prohibited Ingredients](#)
[Reporting Problem Products to FDA](#)
[Shelf Life - Expiration Date](#)
[Voluntary Cosmetic Registration Program](#)

Cosmetic Products that consumers frequently inquire about:

[Animal Grooming Aids](#)
[Aromatherapy](#)
[Artificial Nail Remover](#)
[Eye Products](#)
[Hair Dyes](#)
[Hair Loss Products](#)
[Skin Peeling Products and AHA](#)
[Soap](#)
[Suntan Products, Sunscreens, and Tanning](#)
[Tattooing](#)
[Thigh Creams](#)
[Weight Loss Products](#)

Cosmetic Labeling and Labeling Terms

[Cosmetic Labeling](#)
[Alcohol Free](#)
[Cruelty Free - Not Tested in Animals](#)
[Fragrance Free and Unscented](#)
[Hypoallergenic](#)

Cosmetics of interest to specific groups

[Cosmetics and Teenagers](#)

Cosmetic Help for Cancer Patients
Cosmetic Handbook for Industry

Go [BACK](#) to the CFSAN/FDA food and consumer information page

Updated by dms, 11/1/95

U.S. FDA / Center for Food Safety and Applied Nutrition

Foodborne Illness

[Bad Bug Book -- Foodborne Pathogenic Microorganisms and Natural Toxins](#)

[Foodborne Illness Education Information Center FDA/USDA](#)

[Food Safety Advice for Persons with AIDS](#)

[Handling Eggs Safely at Home](#)

[Healthy People 2000: Food Safety Objectives](#)

[September 1995 Status Report](#)

[Food Safety Objectives, Healthy People 2000](#)

[Can Your Kitchen Pass the Food Safety Test?](#)

Other government sources of information on foodborne illness:

[Food Safety and Inspection Service, U.S. Department of Agriculture.](#)

[Centers for Disease Control and Prevention](#)

contact person for this page is oco@fdacf.ssw.dhhs.gov

Go [BACK](#) to the CFSAN/FDA food and consumer information page

Last updated on 17 Nov 95 by mow@vm.cfsan.fda.gov

US FDA/Center for Food Safety & Applied Nutrition

Food Labeling

Background Information on the New Food Label; Major historical Milestones in Food Labeling; the Food Pyramid- Food Label connection; FDA/USDA Food Labeling Education Information Center and food labeling Publications consumers can order via US MAIL.

Using the New Food Label to lose Weight from brochure by FDA/FTC/NAAG; To cope with Diabetes; To prevent Heart Disease, and to monitor Sodium and other nutrients important to blood pressure

For industry and importers, the Food Labeling Guide and the Q. & A. Vol. I on NLEA Q. & A. Vol. II on NLEA.

Other Federal Agency activities related to the Food Label: FTC Models Advertising Policy and the FDA/USDA Food Labeling Education Information Center USDA Web Server

Facts about Weight Loss products and programs and the New Food Label The New Food Label - Sodium; FDA Consumer Sept. 1994 Vegetarian Diets; and Nutrition and Labeling of Candy

E-Mail questions about contents to oco@fdacf.ssw.dhhs.gov
Go BACK to the CFSAN/FDA food and consumer information page

(Last updated on 10/18/95 by LRD)

US FDA/Center for Food Safety & Applied Nutrition

Imports, Exports, Inspections and HACCP

[Backgrounder on FDA and Imports](#)

[Current Good Manufacturing Practice](#) in Manufacturing, Packing, or Holding Human Food: 21 CFR Part 110

[FDA Enforcement Report](#) (including food products)

[FDA Import Procedures](#) for Industry

[FDA Recall Policies](#) Explained For Industry

[HACCP](#) Hazard Analysis of Critical Control Points in Foods

[Import Alerts](#) for FDA regulated products

[Industry Advisory](#) for seafood exporters to the European Union

[Low Acid Canned and Acidified Foods](#) The FDA Importers Guide

[Procedure for Obtaining Certificates for Export](#) of Foods and Cosmetics

[Recalls](#) FDA, Industry Cooperate to Protect Consumers

[Seafood Information](#)

E-Mail questions about contents to oco@fdacf.ssw.dhhs.gov

Go [BACK](#) to the CFSAN/FDA food and consumer information page

(Last updated 10/22/95 by lrd)

US FDA/Center for Food Safety & Applied Nutrition

Food & Nutrition FDA Press Releases & Fact Sheets

Recent FDA Fact Sheets:

November 7, 1995 Bottled Water Identity Standards [Full Text](#)(700Kbytes)

[Proposed Exemption](#) for Aluminum in Bottled Water

October 6, 1995 Vitamin A and Birth Defects

September 21, 1995 ISSC Vibrio Vulnificus Control Plan for Oysters

August 31, 1995 MSG Talk Paper

April 6, 1995 FDA ALERT: Counterfeit-labeled Similac

March 23, 1995 FDA Cautions Consumers on "Kombucha Mushroom Tea"

February 16, 1995 FDA Pesticides Program

February 10, 1995 FDA Warning against Consuming Bamba Snacks with Peanuts

Recent FDA Press Releases:

July 13, 1995 FDA Announces Food Safety Agencies to Improve Data on Foodborne Illness

May 8, 1995 FDA Announces Food Safety Pilot

February 28, 1995 FDA Warns Consumers against Nature's Nutrition Formula One

Contact oco@fdacf.ssw.dhhs.gov for further content information

Go [BACK](#) to the CFSAN/FDA food and consumer information page

Last updated 11/26/95 by lrd

FDA/Center for Food Safety & Applied Nutrition

Seafood Information and Resources

[Definition of Seafood](#)

[Overview of Seafood Program](#)

[Office of Seafood Organization](#)

[Consumer Advice](#) and [Seafood Hotline](#)


[Decomposition](#) in Seafood

[Economic Deception](#) including the [Seafood List](#) and the [RFE](#) (Regulatory Fish Encyclopedia) with photographic images (JPEG) of selected fish

[Foodborne Disease](#) selected chapters from the Foodborne Pathogenic Microorganisms and Natural Toxins Handbook (Bad Bug Book)

[FDA Pesticides](#) program residue Monitoring Report (10/94) for fish and other products

[HACCP](#) Hazard Analysis of Critical Control Point Program



Other Sources of Seafood Information

[Alaska Seafood Marketing Institute](#) This site contains several brochures providing guidance on the proper handling of seafood.

[Gulf of Mexico Program Information Network](#)

[National Marine Fisheries Service](#)

[Seafood Network Information Center](#) This site contains information on the Seafood HACCP Alliance for Education and Training, Guidance and Regulation (including the text of several FDA documents) and the University of California seafood publications.

Go [BACK](#) to the CFSAN/FDA food and consumer information page

Last updated 11/2/95 by LRD

Other Sources of Food & Nutrition Information

Return to the [CFRAN Food and Consumer Information](#) page

Other U.S. Government Food Safety and Nutrition Sites

- ☐ [U.S. Department of Agriculture \(USDA\)](#)
 - ☐ [Food and Nutrition Information Center National Agricultural Library](#)
 - ☐ [Food Labeling Information USDA Gopher](#)
 - ☐ [Nutrient Databank](#)
 - ☐ [Bureau of Alcohol, Tobacco and Firearms \(ATF\)](#)
 - ☐ [Centers for Disease Control \(CDC\)](#)
 - ☐ [Department of Justice](#)
 - ☐ [Environmental Protection Agency \(EPA\)](#)
 - ☐ [Federal Trade Commission \(FTC\)](#)
 - ☐ [National Marine Fisheries Service \(NMFS\)](#)
-

Non-U.S. Government Sources for Food Safety and Nutrition

- ☐ [Bread Chemistry](#) from Newton's Apple
- ☐ [DFST](#) Division of Food Science and Technology, CSIRO, Australia
 - ☐ DFST's list of other [Food and Nutrition Sites](#)
- ☐ [Food and Agriculture Organization UN FAO](#)
- ☐ [Food and Drug Law Institute](#)
- ☐ [Food Law](#) at University of Minnesota
- ☐ [FoodNet](#) Food Institute of Canada & Agriculture & Agri-Food Canada
- ☐ [Food Safety and Handling](#) at FAIRS (Florida)
- ☐ [Food Safety and Regulation Resources](#)
- ☐ [Food Science Sites](#) at University of Prince Edward Island
- ☐ [INFOODS](#) International Network of Food Data Systems 
- ☐ [IFIC](#) International Food Information Council Foundation
 - ☐ [IFIC Food Color Facts](#)
- ☐ [Institute of Food Research UK](#)
- ☐ [Institute of Food Science and Technology UK](#)
- ☐ [Virtual Nutrition Center](#) Health Science Guide 

Selected commercial sites

Disclaimer

Go back to the [CFRAN Food and Consumer Information](#) page

Last updated at 15:00 on 9/5/95 by [DMS](#)

Information Available on the
Center for Food Safety and Applied Nutrition/FDA
Internet World Wide Web Server

Foodborne Pathogenic Microorganisms and Natural Toxins Handbook

The Center for Food Safety and Applied Nutrition (CFSAN/FDA) has placed on the CFSAN World Wide Web (WWW) Server its Foodborne Pathogenic Microorganism and Natural Toxins Handbook (colloquially known as "The Bad Bug Book"). The Handbook provides information that is general in nature and abbreviated for convenience. Although the book is not intended to serve as a comprehensive reference source, each chapter provides basic facts regarding these organisms and toxins, including their characteristics, habitat or source, associated foods, infective dose, characteristic disease symptoms, complications, recent and/or major outbreaks, and any susceptible populations.

The information in the Handbook has been supplemented by providing internet users immediate linkages to other computer systems containing relevant information on foodborne pathogens and toxins.

- some of the technical terms in the Handbook have been linked to the National Library of Medicine's Entrez glossary system, thereby providing users a brief elaboration of some technical terms,
- selected chapters of the Handbook contain hypertexted links to recent article from the Centers for Disease Control's Morbidity and Mortality Weekly Reports. This feature provides users with the latest information from recent foodborne disease outbreaks and incidents.
- selected chapters of the Handbook contain hypertexted links to the National Library of Medicines' Entrez abstracts of recently published scientific papers. This feature provides users with a bibliography of primary source literature along with abstracts of the papers listed.
- selected chapters of the Handbook contain links to the National Center for Biotechnology Information's GenBank of genetic loci. This feature provides users with direct access to the reported genetic sequences of pathogens.
- selected chapters of the Handbook contain links to other relevant CFSAN, CDC, and FSIS documents, such as educational brochures some of which are in languages other than English.

The Internet WWW version of the Pathogenic Microorganisms and Natural Toxins Handbook provides internet users from around the world with an immense amount of information on foodborne pathogens that previously have not been readily available in one place before. Since the beginning of 1995, the Bad Bug Book pages have been accessed over 35,000 times by approximately 6000 different people. Of that number, 23% were from academic organizations, 15% from government agencies, 15% from commercial organizations, and 27% from organizations outside the US.

New Seafood Page established on the CFSAN World Wide Web

CFSAN has just established a Seafood Page on its World Wide Web (WWW) server consisting of the following information:

- The Regulatory Fish Encyclopedia (a joint project of the Center for Food Safety and Applied Nutrition and the Seattle and San Francisco Districts) was developed to help federal, state, and local officials and purchasers of seafood identify species substitution and economic deception in the marketplace. For 27 of the more frequently consumed fish the Regulatory Fish Encyclopedia on the WWW includes:
 - a color photo of the fish and their filet for visual identification;
 - information on its morphological features, (key measurements), its geographical distribution, and other available reference material; and
 - biochemical gel banding pattern data in a visual and data format.
- The Seafood List, a compilation of existing acceptable market names for imported and domestically available seafood, is provided in a searchable format and with links to the Regulatory Fish Encyclopedia.
- Information from the Bad Bug Book on the seafood-related foodborne pathogens and toxins (with links to relevant CDC and USDA documents).

The CFSAN WWW Seafood page also includes other information of interest to consumers and industry on such topics as HACCP, economic deception, pesticides, and decomposition.

CFSAN has also recently added to its Import, Export, Inspections and HACCP page an industry advisory for seafood exporters to the European Union and links to the FDA Import System which includes access to FDA import alerts.

The WWW URL address for accessing the new CFSAN Seafood Page and the Import, Export, Inspections and HACCP page on the CFSAN WWW server is:

<http://vm.cfsan.fda.gov/list.html>



CDER Executive Secretariat, HFD-8
MetroPark North, Building 1
5600 Fishers Lane
Rockville, MD 20857

CDER Fax on Demand Service ...

(301) 827-0577

To: 3014430235
From: CDER Fax on Demand Service

October 2, 1995 11:47 AM

Please deliver this document to the person at extension 70906

You requested the following documents:
CESS FOD Index

Thank you for using the CDER Fax on Demand Service. You were
caller 2606, received on node 1, line 1.

The CDER Fax on Demand Service is operated by the CDER Executive
Secretariat Staff.

Questions ? : CDER Executive Secretariat (301) 594-1012

Index of Available Documents


	Pages	Updated	Document
<u>CDER/FDA PUBLICATIONS</u>			
Approved Drug Products (Orange Book)	1	04-17-95	07C1
CDER Guideline List	19	08-04-95	07C3
FDA on Disk - Parklawn Computer Center	2	07-20-95	07C2
Federal Register Information	2	08-04-95	07C4
Manuals and Publications	3	03-23-95	07C0
<u>COMMITTEE GUIDANCES</u>			
CMC Info. for Synthetic Peptide Substance	17	04-05-95	08C2
Frmt/Cntnt CMC Section of Annual Report	12	04-05-95	08C1
Sterilization Process Validation in Appl	23	04-05-95	08C0
<u>DRUG APPROVAL PROCESS</u>			
FDA Form 157	2	08-04-95	06C2
FDA Form 1572	2	08-04-95	06C1
Preparation of IND's	12	04-04-95	06C0
<u>GENERIC DRUG INFORMATION</u>			
Acetaminophen, Aspirin, Codeine - Labeli	13	07-03-95	09C5
Acetaminophen, Codeine Oral Solution USP	10	07-03-95	09C6
Acetaminophen, Codeine Tablets	10	07-03-95	09C7
Alprazolol - Labeling Guidance	13	07-03-95	09C3
Amloride - Labeling Guidance	17	07-03-95	09C4
Aterolol - Labeling Guidance	18	07-03-95	09C8
Biopharmaceutic Guidances List	3	04-18-95	09C1
Butalbital, Acetaminophen, Caffeine Tabl	10	07-03-95	09C9
Butorphanol Tartrate - Labeling Guidance	17	07-03-95	0910
Captopril - Labeling Guidance	25	07-03-95	0912
Captopril Hydrochlorothiazide	28	07-03-95	0911
Carbidopa & Levodopa Tablets	9	07-03-95	0913
Cimetidine Tablets - Labeling Guidance	15	07-03-95	0914
Clindamycin Phosphate Inj. USP	17	07-03-95	0915
Diclofenac Delayed-Release Tablets	23	07-03-95	0916
Flurbiprofen Tablets - Labeling Guidance	12	07-03-95	0917
Gentamicin Ophthalmic Solution/Ointment	4	07-03-95	0918
Heparin - Labeling Guidance	14	07-03-95	0919
Hydrapap	11	07-03-95	0920
Labeling Guidances List	4	04-18-95	0900
Leucovor	7	07-03-95	0921
Lomotil	12	07-03-95	0922
Lomotil Tablet	9	07-03-95	0923
Metaprol	8	07-03-95	0924
Metaprol Syr	6	07-03-95	0925
Metaprol Tablet	7	07-03-95	0926
Naproxen	16	07-03-95	0927
Naproxen Tablet	16	07-03-95	0928
Policy & Procedure Guide #41-95	8	04-18-95	09C2
Ranitidine - Labeling Guidance	16	07-03-95	0929
SM-TMP	13	07-03-95	0930
Sulfacet	5	07-03-95	0931
Sulfired	9	07-03-95	0932
Theophyl	33	07-03-95	0933
Tobramyc	15	07-03-95	0934
Verapamil Tablet - Labeling Guidance	15	07-03-95	0935
<u>GMMP GUIDES/GUIDELINES</u>			
GMMP Notes, December 1994 (V2, N4)	11	09-05-95	30C8
GMMP Notes, June 1994 (V2, N2)	8	09-05-95	30C6
GMMP Notes, June 1995 (V3, N2)	8	08-31-95	30C3

Index of Available Documents


	Pages	Updated	Document
CGMP Notes, March 1994 (V2, N1)	9	09-05-95	3005
CGMP Notes, March 1995 (V3, N1)	10	08-31-95	3002
CGMP Notes, September 1994 (V2, N3)	10	09-05-95	3007
CGMP Notes, September 1995 (V3, N3)	9	06-31-95	3004
Guide Inspections Topical Drug Products	6	09-11-95	3000
Guide to Inspec. Bulk Pharmaceutical Che	14	08-18-95	3001
<u>HEALTH CARE PROFESSIONALS</u>			
Health Care Professionals - General Info	2	08-09-95	0102
MedWatch Form	2	04-03-95	0101
MedWatch Instructions	16	04-03-95	0100
<u>HOT TOPICS/ISSUES</u>			
1995 Approvals List	4	08-07-95	0205
Aprostadil	2	07-10-95	0204
Direct-to Consumer, Public Hearing	10	09-08-95	0209
Formula 1 - Talk Paper	3	04-04-95	0201
Kombucha	2	08-15-95	0206
Managed Care Environ., Public Hearing	6	09-08-95	0210
Medication Guide Requirements	9	09-12-95	0211
New OTC Labeling Format	2	06-23-95	0202
Newly Approved Osteoporosis Drug	2	08-21-95	0208
Norplant Update	2	08-18-95	0207
Riluzole for ALS	2	09-21-95	0213
Zocor (simvastatin)	1	07-10-95	0203
<u>MISC GUIDES/GUIDELINES</u>			
Review of Drug Export Amendments 1988	12	08-04-95	4000
<u>NDA GUIDELINES</u>			
Chem Documentation in Radiopharmaceuticals	55	09-11-95	2009
Chemistry, Manufacturing & Controls	13	06-23-95	2003
Format and Content for the Summary	27	07-10-95	2004
Formulating, Assembling, & Submitting New	38	09-08-95	2007
Human Pharmacokinetics/Bioavailability	18	09-11-95	2008
Manufacture of & Controls for Drug Prds.	20	05-04-95	2000
Microbiology Section of an Application	10	05-04-95	2001
Nonclinical Pharmacology/Toxicology	26	08-08-95	2005
Samples & Analytical Data/Methods Validn	19	05-18-95	2002
Submission in Microfiche of the Archival	25	09-22-95	2010
Submitting Documentation for Packaging	30	09-08-95	2006
<u>OTC DRUG ISSUES</u>			
OTC Drug Labeling/Public Hearing	25	08-25-95	5000
<u>POINTS TO CONSIDER</u>			
Clinical Divpmnt-MDI & DPI Drug Products	11	04-21-95	1000



The Center for Biologics Evaluation and Research is on the Information Highway!



The CBER FAX Information System is available 24 hours a day from any FAX machine with a touch-tone telephone.



Requests for documents can be sent to "CBER_INFO@A1.CBER.FDA.GOV". For a list of documents that can be received by INTERNET, send E-mail to "DOC_LIST@A1.CBER.FDA.GOV".

301-594-
1800



An audio information system allows callers to speak directly to knowledgeable staff, obtain employees' telephone numbers, and request documents.

DOCUMENTS AVAILABLE FROM THE CBER
FAX INFORMATION SYSTEM - 301-594-1939

November 28, 1995

<u>Document Number</u>	<u>Document Name</u>
1000	Guideline for Quality Assurance in Blood Establishments, 7/11/95, 36 pages
1001	OELPS, Advertising and Promotional Labeling Staff Procedural Guidance Document (Draft), 8/94, 6 pages
1002	Points to Consider - Characterization of Cell Lines Used to Produce Biologicals, 7/12/93, 42 pages
1003	Points to Consider in Human Somatic Cell Therapy and Gene Therapy, 8/91, 21 pages
1004	Draft Guideline for the Validation of Blood Establishment Computer Systems, 9/28/93, 32 pages
1005	Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology, 4/10/85, 14 pages
1006	Supplement to the Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology: Nucleic Acid Characterization and Genetic Stability, 4/8/92, 9 pages
1007	Draft Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (1994), 43 pages
1008	Points to Consider in the Production and Testing of Interferon Intended for Investigational Use in Humans, 7/28/83, 21 pages
1009	Guideline for Adverse Experience Reporting for Licensed Biological Products, 10/15/93, 56 pages
1010	Draft ICH Document-Analysis of the Expression Construct in Cells Used for Production of R-DNA Derived Protein Products, 5/95, 9 pages
1011	Draft ICH Document-Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products, 5/95, 19 pages
1012	ICH Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, 3/95, 16 pages
1013	Points to Consider in the Manufacture and Testing of Therapeutic Products for Human Use Derived from Transgenic Animals, 8/22/95, 20 pages
1014	Draft Points to Consider for the Evaluation of Combination Vaccines: Production, Testing, and Clinical Study (1995), 10/3/95, 28 pages
*1015	Guidance for Industry; Content and Format of Investigational New Drug Applications (INDS) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products, 11/95, 17 pages

2000 **Schubert/Hopferer/Weinmann / Pages**

2001 1 3 Biologic & Drug Approvals, pages

2002 Advisory Committee Information Line Instructions, 1 page

2003 **Baxter IGIV Talk Paper, 2/25/94, 2 pages**

2004 How to Obtain a Certificate to Foreign Governments, 1 page

2005 How to Make a Freedom of Information Act Request, 1 page

2006 How to Use a Fax Modem with the CBER Fax Information System, 1 page

2007 How to Obtain CBER Documents by Internet Mail, 1 page

2008 How to Obtain CBER Documents by File Transfer Protocol (FTP). 1 page

2010 1994 CBER Approval Actions, 1/10/95, and FDA Talk Paper - 1994 Medication Approvals, 1/17/95, 7 pages

2011 **Press Release and Approval Letter, Varicella Vaccine, 3/17/95, 6 pages**

2012 Information about Export Applications and Requirements, 6/95, 21 pages

2013 Information about Workshop on Characterization of Biotechnology Pharmaceutical Products, to be held December 11-13, 1995, Washington, DC, 2 pages

3000 FEDERAL REGISTER notice - Alternatives to Lot Release, 7/20/93, 3 pages

3001 **FEDERAL REGISTER** notice - Application of Current Statutory Authorities to Human Somatic Cell Therapy, 10/14/93, 3 pages

3002 **FEDERAL REGISTER** notice - Interim Rule - Human Tissue Intended for Transplantation, placed on public display 12/10/93, 9 pages

3003 **FEDERAL REGISTER** notice - Final Rule - Adverse Experience Reporting Requirements for Licensed Biological Products, 10/27/94, 12 pages

3004 **FEDERAL REGISTER** notice - Proposed Rule - Adverse Experience Reporting Requirements for Human Drug and Licensed Biological Products, 10/27/94, 20 pages

3005 **FEDERAL REGISTER** notice - Biological Products; Allergenic Extracts Classified in Category IIIB; Final Order; Revocation of Licenses, 11/16/94, 10 pages

3006 **FEDERAL REGISTER** notice - FDA's Policy Statement Concerning Cooperative Manufacturing Arrangements for Licensed Biologics, 11/25/92, 3 pages

3007 **FEDERAL REGISTER** notice - Home Specimen Collection Kit Systems Intended for Human Immunodeficiency Virus (HIV-1 and/or HIV-2) Antibody Testing; Revisions to Previous Guidance, 2/23/95, 2 pages

3008 **FEDERAL REGISTER notice - Changes to be Reported for Product and Establishment License Applications; Guidance, 4/6/95, 4 pages**

- 3010 **FEDERAL REGISTER** notice - July 27, 1995 - Subcommittee Meeting of the National Task Force on AIDS Drug Development on Drug Development Issues, September 13 & 14, 1995, 2 pages
- 3011 **FEDERAL REGISTER** notice - August 21, 1995 - International Conference on Harmonisation, Draft Guidelines, 11 pages
- 1) Analysis of the Expression Construct in Cells Used for the Production of r-DNA Derived Protein Products
 - 2) Conditions Which Require Carcinogenicity Studies for Pharmaceuticals
 - 3) Detection of Toxicity to Reproduction: Addendum on Toxicity to Male Fertility
 - 4) Stability Testing of Biotechnological/Biological Products
- 3012 **FEDERAL REGISTER** notice - September 27, 1995 - Prominence of Name of Distributor of Biological Products, 6 pages
- 3013 **FEDERAL REGISTER** notice - October 25, 1995 - Characterization of Biological/Biotechnology Pharmaceutical Products; Notice of Public Workshop, 2 pages
- 4000 Memorandum to Registered Blood Establishments, Deferral of Blood and Plasma Donors based on Medications, 7/28/93, 4 pages
- 4001 Memorandum to Registered Blood Establishments, Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products, 7/22/93, 20 pages
- 4002 Memoranda to Registered Blood Establishments, Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV), 8/5/93 and 8/19/93, 9 pages
- 4003 Memorandum to Registered Blood Establishments, Guidance Regarding Post Donation Information Reports, 12/10/93, 3 pages
- 4004 Memorandum to Registered Blood Establishments, Donor Suitability Related to Laboratory Testing for Viral Hepatitis and a History of Viral Hepatitis, 12/22/93, 4 pages
- 4005 Memorandum to Registered Blood Establishments, Recommendations for the Invalidation of Test Results When Using Licensed Viral Marker Assays to Screen Donors, 1/3/94, 5 pages
- 4006 Memorandum to Registered Blood Establishments, Recommendations for Deferral of Donors for Malaria Risk, 7/26/94, 2 pages
- 4007 Memorandum to Registered Blood Establishments, Use of an FDA Cleared or Approved Sterile Connecting Device (STCD) in Blood Bank Practices, 8/5/94 with Transmittal Memo, 8/12/94 (This corrects Memorandum dated 7/29/94), 9 pages

- 4008 Draft Recommendations for the Quarantine and Disposition of Potentially HIV, HCV or HTLV-I Contaminated Units from Prior Collections from Repeat Donors with Repeatedly Reactive Screening Tests. (Intended for discussion at the meeting of the BPAC on 12/15/94.), 11/22/94, 6 pages
- 4009 Memorandum to Registered Blood Establishments, Recommendations to Users of Medical Devices That Test for Infectious Disease Markers by Enzyme Immunoassay (EIA) Test Systems, 12/20/94, 17 pages
- 4010 Memorandum to Registered Blood Establishments, Timeframe for Licensing Irradiated Blood Products, 2/3/95, 1 page
- 4011 Draft Discussion Points for Screening and Testing Donors of Human Tissue Intended for Transplantation and Human Reproductive Tissue, and for Establishment Registration, Intended for discussion at the FDA workshop to be held 1:00 to 5:30 PM on 3/24/95, 3/25/95, 8 pages
- 4012 Draft Background Information for Discussion at the Workshop on Leukoreduced Products on March 27, 1995, 3/9/95, 20 pages
- 4013 Memorandum to Registered Blood and Source Plasma Establishments, Revision of FDA Memorandum of August 27, 1982: Requirements for Infrequent Plasmapheresis Donors, 3/10/95, 3 pages
- 4014 Memorandum to Licensed Establishments Performing Red Blood Cell Immunizations, Revised Recommendations for Red Blood Cell Immunization Programs for Source Plasma Donors, 3/14/95, 6 pages
- 4015 Recommendations for the Deferral of Current and Recent Inmates of Correctional Institutions as Donors of Whole Blood, blood components, Source Leukocytes, and Source Plasma, 6/8/95, 5 pages
- 4016 Draft Document Concerning the Screening and Testing of Donors of Human Tissue Intended for Transplantation, 6/12/95, 9 pages
- 4017 Recommendations for Donor Screening with a Licensed Test for HIV-1 Antigen, 8/8/95, 14 pages
- 4018 Precautionary Measures to Further Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease by Blood and Blood Products, 8/8/95, 6 pages
- 4019 Disposition of Products Derived from Donors Diagnosed with, or at Known High Risk for, Creutzfeldt-Jakob Disease, 8/8/95, 3 pages
- 4020 Recommendations for Labeling and Use of Units of Whole Blood, Blood Components, Source Plasma, Recovered Plasma or Source Leukocytes Obtained from Donors with Elevated Levels of Alanine Aminotransferase (ALT), 8/8/95, 2 pages
- 4021 Guidance for Blood Establishments Concerning Conversions to FDA-Reviewed Software Products, November 13, 1995, 6 pages
- 5000 CBER Organizational Listing, June 1995, 14 pages
- 5001 CBER Organization Charts, July 1995, 26 pages
- 5002 CBER Mission and Vision Statements, 8/14/95, 2 pages

6003 CBER's phone and fax directory, October 11, 1994, 21 pages

6004 CBER Strategic Plan for 2004, 8/14/95, 23 pages

6000 FDA December 17, 1993, Letter to Manufacturers: Bovine Derived Materials (BSE), 3 pages

6001 CBER December 28, 1993, letter describing preliminary position regarding Interim Rule - Human Tissue Intended for Transplantation, 3 pages

6002 Dr. Zoon's Slides - 1/27/95, The State of CBER 1994: The Year of Reinvention, 17 pages

6003 CBER Refusal to File (RTF) Guidance for Product and Establishment License Applications, 7/12/93, 9 pages

6004 CBER March 31, 1994, letter to Blood Establishment Computer Software Manufacturers, 3 pages

6005 Letter to Sponsors of INDs using Retroviral Vectors - 9/20/93, 2 pages

6006 Letter to Sponsors of INDs for Human Immunoglobulin Products - 5/23/94, 4 pages

6007 Review Performance Statistics, September, 1995, 27 pages

6008 Letter to Manufacturers of Licensed Anti-HIV Test Kits - 5/26/94, 4 pages

6009 Letter to IVIG Manufacturers, October 3, 1994, 3 pages

6010 Dear Colleague Letter, Update on the status of efforts to improve the efficiency and effectiveness of the biologic product review and approval program, 11/15/94, 17 pages

6011 Memorandum, OTRR, Alternatives to Lot Release Policy, October 27, 1994, 6 pages

6012 CBER Trends and the Managed Review Process, Dr. Zoon's Slides, 9/19/94, 16 pages

6013 CBER's International Activities, 9/23/94, 6 pages

6014 CBER Update, Dr. Zoon's Slides, 11/2/94, 3 pages

6015 The Role of Science in the Regulation of Biological Products, Dr. Zoon's Remarks at the Dedication of Building 29B, 11/22/94, 7 pages

6016 Statement on FDA Approval of AIDS Virus Test System Based on Oral Fluid Samples, 12/23/94, 2 pages

6017 Letters to Manufacturers of Immune Globulin (Human) - Testing for Hepatitis C Virus RNA, 12/27/94, 2 pages

6018 Letter to Blood Establishment Computer Software Manufacturers, 2/10/95, 5 pages

6019 Letter to Manufacturers of Immune Globulin (Human), 3/3/95, 2 pages

6020 Letter to Manufacturers of Immune Globulin (Human), 3/13/95, 3 pages

6021 Letter to Health Professionals - Market Withdrawal - Plasma Products Produced from Blood Derived from a Donor with Probable CJD, 3/29/95, 5 pages

6022 Background Information - Polson Ivy/Polson Oak Extracts, 3/16/95, 14 pages

6023 Letter to Health Professionals - Market Withdrawal - Plasma Products Produced from Blood Derived from a Donor with Probable CJD, 3/29/95, 5 pages

6024 Addendum to March 29, 1995 Letter - Plasma Product Withdrawal Associated with Probable CJD Donor, 3/31/95, 4 pages

6025 Memorandum to Licensed Manufacturers - Extended Expiration Dating of U.S. Standard Pertussis Vaccine, Lot No. 11, 4/6/94, 1 page

6026 Error and Accident Reports: Summary for First Quarter FY 95 3/22/95, 5 pages, Summary for FY 94, 10/26/94, 22 pages (Total : 27 pages)

6027 Dr. Zoon/Mr. Beatrice Slides, FDA Workshops on Regulatory Policy Issues in the Development & Manufacture of Biopharmaceuticals & Other Biotechnology-Derived Products, 5/95, 6 pages

6028 Dr. Zoon Slides, Drug Information Association, 6/26/95, 6 pages

6029 Error and Accident Reports: Summary for Second Quarter FY-95, 9/22/95, 17 pages

6030 Error and Accident Reports: Summary for Third Quarter FY-95, 9/22/95, 17 pages

6031 Letter to Specific Sponsors, Changes in Lot Release Requirements for Well-Characterized Therapeutic Recombinant DNA-derived and Monoclonal Antibody Products, 11/9/95, 2 pages

7000 Individual Sponsor/Investigator IND Packet, 38 pages

7001 Commercial IND Packet, 73 pages

7002 Application for Establishment License for Manufacture of Biological Products, Form FDA 3210 (6/94), 18 pages

7003 Review Checklists from FDA/CBER Workshop for Licensing Blood Establishments, January 30 & 31, 1995, 27 pages

7004 Establishment & Product License Applications for Manufacturers of Blood and Blood Components [Forms 2599, 2599(a), 2600, 3098, 3098(a), 3098(b), 3098(c), 3098(d), 3098(e), and General Instructions], 28 pages

7005 FDA/CBER Workshop for Licensing Blood Establishments, January 30 & 31, 1995, Slides describing request to use computer crossmatch, 9 pages

7006 Reviewer Guidance, Computer Software, 4/26/95, 4 pages

7007 Draft Reviewer Guidance, Changes in Personnel, 10/95, 1 page

7008 Draft Reviewer Guidance, Informed Consent for Plasmapheresis/Immunization, 10/95, 4 pages

7009 Draft Reviewer Guidance, Disease Associated Antibody Collection Program, 10/95, 2 pages

*7010 Blood Registration Information and Form FD 2830 (08/95), 4 pages

- 1 **Methods of the Allergenic Products Testing Laboratory, October, 1993, 120 pages**
- 8002 **Guide to Inspections of Source Plasma Establishments, Division of Field Investigations, Office of Regional Operations, Office of Regulatory Affairs, December, 1994, 17 pages**
- 9001 **Guidelines, Points-to-Consider, and other guidance documents for Human Biological Products available from the Division of Congressional and Public Affairs, 8/23/95, 11 pages**
- 9002 **Memorandum and Related Documents Pertaining to Human Blood & Blood Products, 8/8/95, 5 pages**
- 9003 **List of Guidelines available from the Center for Drug Evaluation and Research, 20 pages**
- 9999 **Documents Available from the CBER FAX Information System, 7 pages**

* Items added since 11/28/95

DSMA Facts

**CDRH Facts-On-Demand Numbers: 800.899.0381 or
301.827.0111**

DSMA Facts maintained by: Division of Small Manufacturers Assistance (HFZ-220)
Center for Devices and Radiological Health
Food and Drug Administration, 1350 Piccard Drive
Rockville, MD 20850-4307 ☎ Fax 301.443.8818

CDRH Facts-On-Demand (F-O-D) is an automated system that allows anyone access to CDRH information, 24 hours a day, 7 days a week by calling CDRH F-O-D from a touch-tone telephone. Follow the voice prompts and use the telephone keypad to request a DSMA Facts Index or up to three documents. The DSMA Facts Index & documents that are less than 20 pages are faxed to the fax number provided by the requester within a few minutes. Documents that are greater than 19 pages are faxed after normal business hours. To use DSMA Facts:

1. Call CDRH F-O-D from a touch-tone telephone and listen for the initial greeting.
2. Press 1 to access the DSMA Facts section of CDRH F-O-D.
3.
 - a. Press 1 for the current DSMA Facts Index which is updated the first Friday of each month.
 - i. Press 1 to request the current DSMA Facts Index and go to Step 4.
 - ii. Press 2 request up to three documents (see 3.b. for details).
 - b. Press 2 to request up to three documents. Enter the three or four digit Shelf_# from the current DSMA Facts index for each document requested. ***For Shelf_#s greater than 99 drop all leading zeros, e.g. 00702 = 702. For Shelf_#s less than 100, keep 1 or 2 leading zeros to make a 3 digit number, e.g., 00002 = 002 and 00087 = 087.*** The system will prompt you to confirm the number by pressing 1 for *yes* or 2 for *no* on the telephone keypad. Press the pound sign to end document selection and go to Step 4.
4. Enter the telephone number ***including the area code (no leading 1)*** of the fax machine that you wish to receive the document(s) followed by the pound sign. International faxes require the Country/City Code with the telephone number.
5. Enter your telephone number &/or extension number followed by the pound sign for inclusion on the cover page to identify your faxed documents.

< < 1 > >

Index of Available Documents

		Pages	Updated
376	ODE Regulatory Information for the Office of Compliance	1	06-26-95
520	How to Make A Freedom of Information Act Request to FDA	1	08-24-95
653	Recommended Test Methods Infant Apnea Monitor Standard	44	08-22-95
999		1	07-27-95
<u>CENTER DIRECTOR LETTERS</u>			
639	Memorandum Electromagnetic for Medical Devices: Issues and Sc	2	08-22-95
941	Letter to President/CEO on Review Times	7	06-07-95
<u>COMMITTEE/PANEL INFO.</u>			
2001	Advisory Committee Information Line	1	04-19-95
<u>COMPLIANCE POLICY GUIDES</u>			
185	CPG 7150.01, Certification for Exports	8	08-29-95
204	Procedures for Obtaining FDA Approval to Export Unapproved Me	32	09-22-95
<u>COMPLIANCE PROGRAMS</u>			
2702	CPG7382.830 Inspection Med/Dev. Manuf.	48	05-11-95
3702	CPG7382.830 Attach. A, GMP Inspections	39	05-11-95
4702	CPG7382.830, Att A-1 Submission Review	38	05-11-95
5702	CPG 7382.830 Atts B, C, D, E, & F	75	05-11-95
6702	CPG 7382.830 Att G, Model Warning letter	32	05-11-95
7702	CPG7382.830 April 7, 1985 Letter	4	05-10-95
839	Additional FDA Recommendations to the GMP Advisory Committe	2	09-05-95
<u>COMPLIANCE/OTHER</u>			
12	Draft Instructions for Medical Device Listing	11	08-24-95
125	Regulatory Procedures Manual	19	04-18-95
293	Condoms: Inspection and Sampling	14	05-12-95
492	Points to Consider for Internal Reviews and Corrective Action Ope	12	07-11-95
508	A Pocket Guide to Device GMP Inspections	26	07-11-95
786	Inspections of Foreign Device Manufacturers	9	06-30-95
<u>COVERPAGE IMAGES</u>			
9998	Image for top of coverpage	1	06-02-95
9999	image for bottom of cover page	1	06-02-95
<u>FOREIGN REGULATIONS</u>			
1890	Proposed Regulatory Requirements for Medical Devices Sold in C	106	07-12-95
<u>INSTRUCTIONS & INDEXES</u>			
289	How to Order Publications	1	04-21-95
3913	DSMADOC.ALL, sorted by Title	45	06-22-95
488	DSMA Publication Order Form	2	07-11-95
4913	DSMADOC.ONE, sorted by Shelf_#	41	06-22-95
5913	DSMADOC.DAT, sorted by Doc_Date	44	06-22-95
6913	DSMADOC.LOG, sorted by Login_Date	44	06-22-95
919	DSMA Facts Index	8	10-05-95
<u>MDR POLICIES/GUIDELINES</u>			
174	MDR Guidance Document No. 4 - External Defibrillators	3	08-24-95
188	Remedial Action Exemption	3	06-30-95
216	Guidance on Medical Device Reporting of Incidents Involving Intra	4	08-24-95
250	MDR Guidance Document No. 3 - Needlesticks and Blood Exposu	3	08-24-95
451	MDR Policy/Guidance for Endosseous Implant Devices	1	08-24-95
452	MDR Reporting Guidance for Breast Implants	2	08-24-95
498	Availability and Use of Standard Medical Device Reporting Forms	16	07-12-95
509	An Overview of the Medical Device Reporting Regulation	18	07-12-95

Index of Available Documents

		Pages	Updated
557	Medical Device Reporting for User Facilities Questions and Answers	50	07-12-95
<u>ODEBLUE BOOK</u>			
007	PMA/510(k) Expedited Review	4	04-13-95
030	Diagnostic Ultrasound Equipment & Related	4	04-13-95
031	Consolidated Review for Lasers/Access.	4	04-14-95
034	Final Draft Medical Device Labeling	2	04-14-95
035	510(k) Computer Controlled Medical Dev.	2	04-14-95
276	ODE Regulatory Information for OC	1	04-18-95
280	Panel Review of "Me-Too" Devices	1	06-09-95
289	Premarket Notification Review Program	16	04-20-95
291	ODE Mentor Program	2	04-20-95
292	Training Checklist for New Reviewers	3	04-21-95
294	Tripartite Biocompatibility Guidance (#G)	8	03-28-95
297	PMA Filing Decisions	13	04-21-95
301	PMA Summaries of Safety/Effectiveness	2	04-21-95
302	PMA's Early Review/Preparation Summaries	3	04-21-95
304	Criteria for Panel Review PMA Supplement	6	04-21-95
305	Review and Approval of Licensee PMAs	3	04-21-95
306	Panel Report and Recommendations PMA	7	04-25-95
308	510(k) Sign-off Procedures	4	04-21-95
328	Blue Book #86-1, Media Contacts	2	06-09-95
330	Blue Book #88-1, Review of Laser Submissions	2	06-09-95
331	Delegation of IDE Actions	5	08-22-95
333	PMA Review Schedules	2	08-26-95
334	ODE Guidance Memoranda (Blue book) Table of Contents	4	08-22-95
357	Sabbatical Program for ODE Reviewers	2	08-26-95
360	Telephone Communications Between ODE Staff and Manufacturer	6	08-26-95
361	510(k) Sterility Review Guidance; Blue B	19	04-07-95
362	Review of IDEs for Feasibility Studies	6	06-26-95
365	Integrity of the Medical Device Review Program	1	06-26-95
366	Assignment of Review Documents	1	06-26-95
368	Policy Development and Review Procedures	1	06-23-95
369	Training for ODE Reviewers	5	06-23-95
3859	510(k) Refuse to Accept Policy	10	05-10-95
387	When PMA Supplements are Required	7	06-23-95
388	ODE Peer Review Promotion Process	2	06-26-95
389	Approval of Speaking Engagements	2	06-26-95
401	510(k) Refuse to Accept Procedures	3	08-22-95
402	PMA Refuse to File Procedures	4	08-22-95
404	PMA/510(k) Triage Review Procedures	3	08-22-95
405	Goals and Initiatives for the IDE Program	8	08-24-95
409	Implementation of the FDA/HCFA Interagency Agreement Regarding	15	08-28-95
412	Document Control Procedures	4	06-30-95
413	510(k) Independent Quality Review Program	2	06-30-95
414	Device Labeling Guidance	13	06-30-95
443	Clinical Utility and Premarket Approval; P91-1	3	07-11-95
444	Panel Review of Premarket Approval Applications; P91-2	4	07-11-95
445	PMA Compliance Program; P91-3	6	07-11-95
446	Document Review Processing; I91-1	6	07-11-95
447	Integrity of Data and Information Submitted to ODE	1	07-12-95
4859	IDE Refuse to Accept Policy	12	05-10-95
5859	PMA Refuse to File Policy	13	05-10-95
587	Nondisclosure of Financially Sensitive Information	5	07-12-95
622	Training for Supervisors	7	08-24-95
931	Proposal for Setting Review Priorities U	14	03-28-95
<u>ODEVCLD GUIDANCE</u>			
051	INVDD Thyroid Autoantibodies IFA/HA	16	04-14-95

Index of Available Documents

		Pages	Updated
082	Blood Culture Systems	16	04-13-95
083	Devices for Diagnosing Lyme Disease	21	04-13-95
095	Collection Data INVDD Submissions 510k	10	04-14-95
272	Home use IVDs	14	04-13-95
285	Monoclonal Antibody Products/Human Use	23	04-21-95
339	Premarket Notification - Consistency of Reviews	2	07-12-95
364	Draft Guidance for Submission of Immunohistochemistry Applicati	48	08-28-95
417	Cytogenic Analysis	15	04-13-95
459	Review Criteria for Assessment of Alpha-Fetoprotein (AFP) In Vitro	34	07-12-95
475	Lymphocyte Immunophenotyping Monoclonal	8	04-13-95
494	letter dated 10-17-1991	8	07-12-95
518	Hepatitis A Virus, total & IgM Antibodie	12	04-13-95
527	Review Criteria for In Vitro Diagnostic Devices for Detection of IGA	15	07-12-95
564	Guidance Criteria for Cyclosporine PMAs	17	03-10-95
588	Review Criteria for Assessment of Laboratory Tests for the Detecti	13	07-12-95
603	Estrogen or Progesterone Guidance	23	04-13-95
604	Blood Glucose IVD	13	04-13-95
605	Guidance for 510(k)s on Cholesterol Tests for Clinical Laboratory,	26	07-14-95
615	Draft FDA Guidance to Manufacturers of In Vitro Analytical Test S	59	08-22-95
629	C Difficile Associated Diseases	10	04-13-95
631	Antimicrobial Susceptibility	26	08-22-95
658	Glycohemoglobin (Glycated or Glycosylate	18	04-13-95
663	Review Criteria for Assessment of Cholesterol In Vitro Diagnostic I	33	09-15-95
770	Review Criteria For Premarket Approval of In Vitro Diagnostic Dev	13	08-22-95
772	Draft Guidance Document for 510(k) Submission of Fecal Occult E	17	07-26-95
778	INVD Detection of Chlamydiae in Specimen	17	04-07-95
800	Allergen-Specific Immunoglobulin E (IEG)	19	04-08-95
848	Review Criteria for Assessment of Anti-Nuclear Antibodies (ANA) I	21	08-22-95
927	DCLD Tier Categorizations (Triage Lists)	19	04-07-95

ODE/DCRND GUIDANCE

037	Draft DCRND 510(k) Guidance	12	04-14-95
054	510(k) for Processed Human Dura Mater	5	03-29-95
124	Protocol for Dermal Toxicity Testing for	11	04-13-95
141	Automated/Manual Defibrillators Checklis	2	04-17-95
143	Biofeedback Devices/Draft Guidance 510k	6	04-17-95
207	Premarket Notification Review Guidance for Evoked Response So	2	06-30-95
208	Draft Version - Guide for Cranial Electrode 510(k) Content	5	06-30-95
209	Draft Version - Guidance for Clinical Data to be Submitted for Pre	8	06-30-95
212	Draft Version - Cranial Perforator Guidance	8	06-30-95
214	Draft Version - Neuro Endoscope Guidance	10	06-30-95
215	Galvanic Skin Response Measurement Devices - Draft Guidance	6	06-30-95
224	Guidance: Human Heart Valve Allografts	35	04-18-95
300	Guide for TENS 510(k) Content	6	06-30-95
347	Premarket Notification Guide for Breathing Frequency Monitors (A	15	06-28-95
354	Powered Muscle Stimulator 510(k) Submiss	9	03-30-95
370	Balloon Valvuloplasty Guidance for IDE/PM	10	03-30-95
372	Implantable Pacemaker Lead Testing Guida	6	03-30-95
373	IDE for Laser Devices used in Atheroscle	11	03-30-95
374	Guidance for the preparation and Content of Applications to the FI	34	06-23-95
375	Draft Replacement Heart Valves - Guidance for Data to be Submit	94	07-28-95
377	Guidance for Safety and Effectiveness Data Required in Premarke	5	06-26-95
378	PTCA Catheter System Testing Guidance	10	03-30-95
380	Cardiovascular Ultrasound Indications fo	1	03-31-95
382	510(k) for Intraortic Balloon Catheter	9	03-31-95
383	Implantable Pacemaker Testing Guidance	9	03-30-95
385	Second Draft Proposed Standard for the Infant Apnea Monitor	67	06-23-95
391	Letter to Vascular Graft Manufacturer, Developer, or Representativ	23	08-29-95
500	Draft Reviewer Guidance for Ventilators	30	08-15-95

Index of Available Documents

		Pages	Updated
550	Treacheostomy Tubes; Reviewer Guidance	1	03-31-95
563	Analysis of Explant Replacement Heart	3	03-31-95
582	Annual Report to the PMA Approved Heart	4	03-31-95
583	Oxygen Conserving Device 510(k)	2	03-31-95
593	Guidelines for Reviewing Premarket Notifications that Claim Subst	2	08-22-95
594	510(k) for CO2 Lasers for Neurosurgery	2	03-31-95
627	Draft Guidance on Biocompatibility Requirements for Long Term Im	5	08-22-95
638	Excerpts Related to EMI from November 1993	18	08-15-95
640	Guidance for Studies for Pain Therapy De	15	03-31-95
646	Rationale For Requirements Infant Apnea Monitor Standard	28	08-22-95
654	Additional Guidance for Testing Immunity to Radiated Electromag	11	08-22-95
763	Draft 510(k) Checklist for Sterilization Wraps	4	08-22-95
764	Draft of 510(k) Checklist for Through-Put Process Indicators	2	08-22-95
780	Heated Humidifier Review Guide	3	04-04-95
781	Reviewer's Guidance Oxygen Concentrator	1	08-22-95
782	Guidance for Ventilator Evaluations	3	04-04-95
783	Catheter Guidance	2	04-05-95
784	Nebulizers/Metered Dose Inhalers/Spacers	6	04-06-95
846	Guidance for the Submission of Research and Marketing Applicati	65	07-26-95
928	DCRND Tier Categorizations (Triage Lists	19	04-07-95
 <u>ODE/DGRD GUIDANCE</u>			
028	510(k) Guidance for Resorbable Periodont	7	03-08-95
033	Calcium Phosphate Coating Draft Guidance	16	03-17-95
085	510(k) for Temporomandibular Joint Impla	11	04-14-95
086	Premarket Notification Endosseous Implan	7	04-14-95
087	Clinical Investigation Endosseous Implan	6	04-14-95
088	Animal Lab Studies Endosseous Implants	4	04-14-95
090	Hydroxyapatite/Titanium Endoss. Implants	3	04-14-95
091	Ti-Powder/Titanium Endosseous Implants	3	04-14-95
092	510(k) Metallurgical Endosseous Implants	2	04-14-95
093	Surface Characteristics of Implant Metal	2	04-14-95
064	Galvanic Corrosion of Implant Metals	2	04-14-95
108	510(k) for Sun Protective Clothing	17	04-14-95
133	Spinal Fixation Device Systems	11	04-17-95
144	Silicone Gel-Filled Breast Prostheses	29	04-17-95
145	Checklist Air Cleaners/Air Purifiers	3	04-17-95
146	Testing of Alternative Breast Prostheses	11	04-17-95
165	Letter to Medical Glove Manufacturers	13	06-26-95
180	Data Requirements for Ultrahigh Molecular Weight Polyethylene (L	4	06-29-95
187	Guidance Document for Femoral Stem Prostheses	12	06-29-95
233	Intra-Articular Prosthetic Knee Ligament	64	04-19-95
234	IDE & PMA guidance for Bone Growth Stimu	29	03-29-95
252	Biodegradable Fracture Fixation	12	03-29-95
314	Kits with sutures	2	06-07-95
315	Establishment of ODE policy for labeling surgical suture size	4	06-07-95
336	FDA Technical Publications on Orthopedic Devices and Biomateri	4	06-26-95
353	PMA for Endosseous Implant for Prostheti	23	03-29-95
355	510(k) for Ceramic Ball Hip Systems	10	03-29-95
366	Guidance on the content and Organization of a Premarket Notifica	29	06-30-95
392	510(k) for Implanted Infusion Ports	26	03-29-95
424	Draft Guidelines for the Premarket Testing and Labeling of Antimic	22	06-30-95
450	510(k) for Hypodermic Single Lumen Needl	16	03-31-95
532	Draft Guidance for Preparation of PMA Application for Silicone Inf	46	07-26-95
576	Guidance on the Content and Format of Premarket Notification (5	50	07-12-95
623	Metallic Surface Treated Orthopedic Impl	15	03-31-95
636	Draft Guideline for Reviewing Spinal Fixation Device Systems	6	08-22-95
689	Guidance document for the Preparation of Premarket Notification	13	09-15-95
729	Guidance Document for the Preparation of Premarket Notification	13	09-15-95

Index of Available Documents

		Pages	Updated
735	Guidance document for the Preparation of Premarket Notification [	13	09-15-95
762	Guidance document for the Preparation of Premarket Notification [	14	09-15-95
790	Screw Type Endosseous Implant/Prosthesis	10	04-08-95
818	Guidance document for the Preparation of Premarket Notification [	11	09-15-95
821	510(k) for Piston Syringes	21	03-29-95
822	Clinical Electronic Thermometers	18	04-07-95
823	510(k) Submission External Infusion Pump	19	04-07-95
824	Short/Long Term Intravascular Catheters	19	08-22-95
827	Orthopedic Implants with Metallic/Bone	8	04-07-95
828	Guidance document for the Preparation of Premarket Notification [	11	09-15-95
830	510(k) - Cemented Semi-Constrained Knee	8	04-07-95
832	510(k) Applications for Orthopedic Device	9	07-13-95
833	Guidance on Premarket Notification [510(k) Submissions for Steril	34	07-28-95
895	Guidance on the Content and Format of Premarket Notification [5	8	09-22-95
909	Draft Guidance for Arthroscope and Accessory 510(k)s	7	09-22-95
929	DGRD Tier Categorization (Triage Lists)	23	04-07-95
934	Supplementary Guidance on the Content of Premarket Notification	34	09-15-95

ODE/DOD GUIDANCE

055	Guidance Document Multifocal Intraocular	13	03-08-95
079	Labeling for UV absorbing Contact Lenses	2	04-13-95
109	IDE - Excimer Laser Device/Myopic PRK	12	04-14-95
256	Suggestions Contact Lens Prod. Labeling	46	05-12-95
266	Yag Laser for Ophthalmic Surgery	12	04-18-95
275	Class III Soft Hydrophilic Contact Lens	70	04-19-95
309	Safety/Labeling Req. for Heat Disinfecti	14	04-25-95
310	Policy Requirements for IOLs: IDE/PMA	12	05-10-95
312	Annual Report in Place PMA Supplements	9	04-25-95
316	Report on Intraocular Lenses (IOLs) Adju	22	03-28-95
317	30 Day Approval of Premarket Approval Application Supplements	24	06-07-95
318	Letter to Contact Lens Industry on elimination of some requiremen	3	06-07-95
319	New Procedures for implementing Changes in Contact Lens Packu	3	06-09-95
320	New Procedures for implementing Changes in Contact Lens Soluti	3	06-09-95
321	New Requirements for Investigations of A	8	03-28-95
322	Adverse Reaction reporting for IOLs	3	06-09-95
394	sterilant residue letter	2	06-29-95
395	IOL letter re: PMA guidance	13	06-29-95
396	Dear IOL Sponsor letter	4	06-29-95
397	IOL Sponsor letter re: IDE	3	06-29-95
514	FDA Guidance for Photorefractive Keratectomy Laser Systems: ID	113	09-15-95
767	Guidance Document Approval Requirements for IOLs with an Exte	10	09-28-95
793	Sutured PC Intraocular Lenses: Proposed	21	03-29-95
794	IOL Adjunct Study Phase-out	4	03-29-95
795	Guidelines for Intraocular Devices	39	07-12-95
930	DOD Triage List	5	03-29-95

ODE/DRAER/D GUIDANCE

096	Premarket Notification/Urine Drainage Ba	5	04-14-95
097	Conventional/Antimicrobial Foley Cathete	11	04-14-95
098	Checklist Lithotripters/Stoned Dislodger	5	04-14-95
099	Checklist Conditioned Enuresis Alarms	3	04-14-95
100	Clinical Studies Vasovestostomy Devices	4	04-14-95
134	Gastroenterology/Urology Device Tier	4	04-17-95
161	Draft Guidance for Preparation of PMA Applications for the Implan	38	09-22-95
162	Draft Guidance for the Content of Premarket Notifications for Endc	14	09-22-95
166	Draft Guidance for the Content of Premarket Notifications for Mens	28	06-30-95
177	Draft Guidance for the Content of Premarket Notifications for Penil	14	06-28-95
189	Draft 510(k) Checklist for Non-implanted Electrical Stimulators use	11	06-30-95
190	Draft 510(k) Checklist for Endoscopic Light Sources used in Gastr	7	06-30-95

Index of Available Documents


		Pages	Updated
182	510(k) Guidance for 2-D Laparoscope	6	06-28-95
202	Guidance to Manufacturers on the Development of Required Posts	2	06-28-95
232	Laparoscopic Bipolar/Thermal Coagulator	6	04-17-95
244	Evaluation of Fetal Clip Electrodes	4	03-29-95
245	Tubal Occlusion Devices	7	04-13-95
248	Hysteroscopic Sterilization Devices	9	04-18-95
281	Acoustic Output of Diagnostic Ultrasound	93	04-20-95
323	All U.S. Condom Manufacturers, Importers and Repackagers	5	06-08-95
327	Cochlear Implant Guidance	24	03-10-95
335	Necessary Information for Diagnostic Ultrasound 510(k)	8	08-24-95
358	Doppler Ultrasound Instrumentation	33	06-28-95
384	Female Barrier Contraceptive Devices	16	03-31-95
388	Condom letter	44	06-29-95
416	Picture Archiving and Communications Sys	9	03-31-95
418	Extracorporeal Shock Wave Lithotripsy	14	03-31-95
421	Guidelines for Premarket Testing of New Conventional Hemodialyz	16	06-30-95
431	510(k) for Ureteral Stents	6	03-31-95
455	Testing Guidance for Non-Latex Male Condoms	14	07-12-95
464	510(k) for Air Conduction Hearing Aid	11	03-31-95
482	Guidance for the Content of Premarket Notifications for Biopsy De	8	07-12-95
490	Guidance for the Content of Premarket Notifications for Urodynam	10	07-12-95
515	Draft 510(k) Checklist for Urological Irrigation System and Tubing	7	08-15-95
533	Benign Prostatic Hyperplasia (BPH)	16	03-31-95
567	510(k) for Urological Balloon Dilation C	11	03-31-95
577	Guideline for the Arrangement and Content of a Premarket Approv	26	07-12-95
641	Guidelines for Evaluation of Non-Drug IUDs	16	08-22-95
657	Draft Guidance to Hearing Aid Manufacturers for Substantiation of	7	07-26-95
768	Draft 510(k) Checklist for Endoscopic Electrosurgical Unit (ESU) a	7	09-28-95
788	Automatic X-Ray Film Processor 510(k)	2	04-06-95
791	Guidance for the Technical Content of a Premarket Approval (PMA)	3	07-26-95
806	Draft Guidance for Preparation of PMA Application for Testicular F	51	08-22-95
810	Draft Guidance for Preparation of PMA Applications for Penile Infl	55	07-26-95
820	Premarket Testing Guidelines for Home Uterine Activity Monitors	60	08-22-95
842	Draft Guidance for the Content of Premarket Notifications for Wat	11	09-28-95
928	DRAERD Tier Categorizations Triage Lists	14	04-07-95
932	DRAERD Triage Pilot Program	13	04-07-95
991	510(k) Checklist for Condom Catheters	3	08-22-95
992	Draft Guidance for the Content of Premarket Notifications for Ext	14	06-29-95
<u>ODEVOTHER GUIDANCE</u>			
078	Perspectives on Clinical Studies	10	04-13-95
084	PMA Review Statistical Checklist	2	04-14-95
147	Premarket Submission Cover Sheet	18	03-29-95
160	Third Party Review of 510(e), Pilot	19	05-30-95
164	Use of International Standard ISO-10993, "Biological Evaluation o	6	06-30-95
198	Labeling Reusable Medical Devices for Reprocessing in Health Ca	25	06-29-95
223	Latex Bibliography	3	04-18-95
225	Conducting Recall Effectiveness Checks	10	04-17-95
226	Medical Device Reporting	2	04-17-95
228	Suggestions - Submitting PMA Application	2	04-17-95
2337	510(k) Software Documentation Matrix, Page 16 of the Reviewer C	1	07-11-95
236	Microwave Diathermy Equipment	6	04-17-95
247	GMP/Computerized Device/Manufacturing	28	04-17-95
267	GMP to the Manufacture of Sterile Device	14	04-18-95
268	Color Additive Status List	10	04-18-95
269	Characterization Cell Line/Biological Pr	64	05-18-95
274	Electrical Muscle Stimulator	2	04-18-95
283	Biological Indicator Incubation Time	4	04-19-95
284	Hybridoma In Vitro Diagnostic Products	4	04-20-95

Index of Available Documents

		Pages	Updated
286	Calibration Intercomparison Microwave	24	04-20-95
287	Significant and Nonsignificant Risk Devi	10	04-20-95
288	Clinical Investigator Information Sheets	54	05-11-95
295	Preproduction Quality Assurance Planning: Recommendations for	25	06-07-95
296	Color Additive Petitions	2	04-21-95
298	ODE Guidance Documents FY86 - FY87	6	04-21-95
311	Suggested Format IDE Progress Reports	1	04-25-95
329	Information for Executive Secretaries of ODE Advisory Panels	4	08-09-95
337	Reviewer Guidance for Computer Controlled Medical Devices Und	43	06-26-95
338	Part III - Guidance on Scientific and Technical Information: Master	7	06-22-95
351	FDA Policy for the Regulation of Computer Products	3	06-28-95
352	Threshold Assessment of the Impact of a Requirement for Submis	8	06-28-95
359	Directory of Companies Performing Primary Skin Irritation and Hui	10	06-28-95
363	Toxicology Risk Assessment Committee	4	06-28-95
367	Meetings with the Regulated Industry	3	06-28-95
371	4-Of-a-Kind PMAs	2	06-23-95
390	510(k) "Substantial Equivalence" (SE) Decision Making Document	5	06-29-95
415	Shelf life of Medical Devices	26	06-30-95
420	Product Development Protocol Guideline	22	06-30-95
423	Guideline for Preparing Notices of Availability of Investigational Me	4	06-30-95
425	Principles of Process Validation	13	04-03-95
426	Guideline on Sterile Drug Products Produced by Aseptic Processin	44	06-30-95
427	Guideline on Validation of the Limulus Amebocyte Lysate Test as	44	06-30-95
428	Guideline for the Monitoring of Clinical Investigations	9	07-11-95
448	Guidance of Preparation of PMA Manufacturing Information	12	07-12-95
487	Premarket Notification Certification and Summary	1	07-11-95
497	Required Postmarket Surveillance Guidance	14	07-12-95
575	Color Additive for Medical Devices	13	07-12-95
584	Preamendments Class III Devices	13	07-12-95
596	Premarket Notification Truthful and Accurate Statement	3	08-24-95
597	Premarket Notification Class III Certification and Summary	2	08-24-95
598	Premarket Notification 510(k) Statement	2	08-24-95
607	Device, Drug or Cosmetic	27	08-24-95
609	Petition to Reclassify	11	08-24-95
613	Automatic Detention of Medical Devices	6	08-24-95
671	List of Contract Sterilizers	5	08-24-95
806	Radiation Exposure from Medical Imaging Demonstrations	3	09-15-95
814	Certified Color Manufacturers	4	08-24-95
815	Device Specific Guidance Documents	8	08-24-95
829	Biocompatibility of Medical Devices	25	08-24-95
858	Premarket Notification [510(k)] Status R	1	03-20-95
912	Addendum: How to Submit a Premarket Notification [510(k)]	16	06-06-95
935	Deciding When to Submit a 510(k) for Cha	37	08-14-95
936	Attachments to: Deciding When to Submit	5	08-14-95
937	Premarket Approval Applications	10	09-26-95
939	Medical Device Exemptions	15	07-25-95
<u>POSTMARKET SURVEILLANCE/OTHER</u>			
206	Guidance to Sponsors on the Development of a Discretionary Post	16	06-30-95
422	Medical Device Notification and Voluntary Safety Alert Guideline	13	06-30-95
<u>RAD HEALTH - TELEVISION</u>			
259	Television Receivers & Video Display Terminals, testing requirem	29	06-07-95
<u>RAD HEALTH - SUNLAMPS</u>			
348	Reporting Guide for Initial Reports and Model Change Reports on	18	06-26-95
<u>REGULATIONS/OTHER</u>			
393	Table 1 - Comparison of Drug and Device Good Manufacturing Pri	16	06-29-95

Index of Available Documents

		Pages	Updated
411	Suggested Changes to the Medical Device Good Manufacturing Pr	30	06-30-95
419	Petition Guidelines on Exemption or Variance from the Device GM	7	06-30-95
<u>UNCODIFIED REGULATIONS</u>			
1030	Docket 95N-0139; Proposed Reclassification & Exemption of Cert	84	07-31-95
1031	Docket 94M-0260; Exemption from 510(k) for Certain Medical Dev	15	07-31-95
1032	Docket 91N-0063; Revocation of the Exemption from 510(k) for BI	10	07-31-95
1033	Docket 94M-0260	5	07-31-95
1303	Notice of Availability, Working Draft of the Current GMP Final Rule	7	07-31-95
2303	Preamble - Working Draft of the Current GMP Final Rule July 199:	89	07-27-95
3303	Regulation - Working Draft of the Current GMP Final Rule July 199	20	07-31-95
<u>VIDEO & TELECONFERENCES</u>			
921	May 4, 1995 Video Conference at 1:00 PM	1	04-11-95

FACSIMILE TRANSMISSION SHEET**FROM: LINDA A. VOGEL****Director
Office of International and
Refugee Health****Department of Health and Human Services
5600 Fishers Lane
Rockville, Md. 20857
RM.18-75****TEL: 301-443-1774
FAX: 301-443-6288
E-Mail: LVOGEL.OASH
Internet: LVOGEL@OASH.SSW.DHHS.GOV****OFFICE OF INTERNATIONAL AND REFUGEE HEALTH**

TO: Ms. Lahoma Romacki **FAX NUMBER: 202-632-1096**
DATE: 12/12/95 **NUMBER OF PAGES: 3**
(INCLUDING COVER SHEET)

☐ **FYI**
☐ **AS REQUESTED**☐ **FY ACTION**
☐ **AS DISCUSSED****MESSAGE:**



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Memorandum

Date . December 11, 1995

From Director
Office of International Health

Subject International Health Representatives Meeting - December 14, 1995

To Addressees

The next PHS International Health Representatives' Meeting will be held on Thursday, December 14, 1995, from 2:00-4:00 p.m. in the Parklawn Building, in room 17-09.

As we reach the close of this year, I felt it might be useful for us to have a brief look at the last year (what were the most important initiatives/activities internationally for each agency) and look forward to 1996 (what are the most important activities that we should be focusing on during 1996?). We are asking each agency/office to come prepared to briefly address these two questions.

DRAFT AGENDA FOR MEETING

- ◆ Year in Review and Looking Forward to 1996
(Agencies/offices are being asked to speak briefly, from their agency's/office's perspective, on the three most important activities/initiatives in 1995 and on the three highest priorities for 1996. These may be issue specific or program specific.)
- ◆ Bilateral Programs
 - Planning for Gore-Chernomyrdin VI, Jan. 1996
 - Gore-Mbeki Commission Meeting and Secretary's Trip to Africa
 - Mexico - Secretary's Trip
 - Other
- ◆ Agency Reports


Linda A. Vogel

Page 2

Addressees

Dr. Jo Ivey Boufford, PDASH
Mrs. Barbara Cohen, OPA/OPHS
Dr. Susan Blumenthal, OWH/OPHS
Mr. Bruce Chelikowsky, IHS
Dr. Mary Cummings, AHCPR
Dr. Joe Davis, CDC
Mr. George Dines, HRSA
Ms. Julia Plotnick, HRSA
Dr. Philip Schambra, NIH
Ms. Linda Staheli, NIH
Ms. Georgia Buggs, OMH/OPHS
Mr. Stephen Sawmelle, SAMHSA
Dr. George Coelho, SAMHSA
Ms. Sharon Smith Holston, FDA
Dr. Stuart Nightingale, FDA
Mr. Walter Batts, FDA
Mr. James Harrell, ODPHP/OPHS
Dr. Linda Myers, ODPHP/OPHS
Dr. Frank Young, OEP/OPHS
Ms. Ellen Shippe, DOS/STH
Mr. Anthony Rock, DOS/STH
Mr. Joseph Baldi, HRSA
Ms. Lahoma Romacki, NAPO
Dr. Robert Hartford, NCHS
Mr. David Hohman, OS
Mr. Ronald Lorton, DOS/SCP
Mr. David Oot, AID
Dr. Eric Goosby, AIDS
Dr. Elaine Daniels, NAPS
Dr. Juan Ramos, NIMH/NIH
Dr. Faye Calhoun, NIAAAA/NIH
Dr. Pat Needle, NIDA
Dr. Glen Post, USAID
Ms. Carol Dabbs, USAID
Dr. Noreen Hynes Carus, Peace Corps
RADM Stephen Corbin, OSG
OIH Staff - AID and Parklawn



Memorandum

Date . November 9, 1995

From * Director
Office of International and Refugee Health

Subject . International Health Representatives Meetings - 1996 CALENDAR

To Addressees

The following is a calendar for the International Health Representatives Meetings for calendar year 1996. Following the practice established last year, the meeting will generally be held on the second Thursday of each month from 2:00 to 4:00 p.m. You will be notified of the meeting rooms.

January 11, 1996

February 8, 1996

March 14, 1996

April 11, 1996

May 9, 1996

June 13, 1996

July 11, 1996

August 8, 1996

September 12, 1996

October 10, 1996

November 14, 1996

December 12, 1996

We will do our best to stick with this schedule, but there is always the possibility that a specific meeting may have to be canceled due to circumstances at the time. All addressees of this memorandum will be notified by telephone.


Linda A. Vogel

Page 2 - Addressees

Dr. Jo Ivey Boufford, PDASH
Mrs. Barbara Cohen, OPA/OASH
Dr. Susan Blumenthal, OWH/OASH
Mr. Bruce Chelikowsky, IHS
Dr. Mary Cummings, AHCPR
Dr. Joe Davis, CDC
Mr. George Dines, HRSA
Ms. Julia Plotnick, HRSA
Dr. Philip Schambra, NIH
Ms. Linda Staheli, NIH
Ms. Georgia Buggs, OMH/OASH
Mr. Stephen Sawmelle, SAMHSA
Dr. George Coelho, SAMHSA
Ms. Sharon Smith Holston, FDA
Mr. Walter Batts, FDA
Dr. Stuart Nightingale, FDA
Mr. James Harrell, ODPHP/OASH
Dr. Linda Myers, ODPHP/OASH
Dr. Frank Young, OEP/OASH
Mr. Joseph Baldi, HRSA
Dr. Eric Goosby, HIV/AIDS
Ms. Lahoma Romacki, NAPCO
~~Mr. Sam Notzon, NCHS~~
Dr. Eric Goosby, AIDS
Dr. Juan Ramos, NIMH/NIH
Dr. Faye Calhoun, NIAAA/NIH
Ms. Dorothea Dezafra, NIAAA
Dr. Pat Needle, NIDA
CAPT Stephen Corbin, OSG
Dr. Glen Post, USAID/AFR
Ms. Carol Dabbs, USAID/LAC
Dr. Noreen Hynes Carus, Peace Corps
Mr. David Hohman, OS
Mr. Ronald Lorton, DOS/SCP
Mr. David Oot, AID
Ms. Ellen Shippe, DOS/STH
Mr. Anthony Rock, DOS/STH
OIH Staff - AID and Parklawn



Memorandum

Date .November 17, 1995

From Director
Office of International and Refugee Health

Subject Follow-up on November International Health Representatives'
Meeting - Secretary's Speech at APHA

To International Health Representatives

Attached, as promised at our recent International Health Representatives' meeting, is a copy of the Secretary's speech at the October 31 American Public Health Association meeting.

A handwritten signature in cursive script, appearing to read "Linda", is positioned above the printed name.

Linda A. Vogel

Attachment

Safe Passages:

Helping Teenagers, Helping Families, and Helping You

Donna E. Shalala

Secretary of Health and Human Services

The American Public Health Association Annual Conference

San Diego, California

October 31, 1995

I'd like to begin by telling you a tragic and haunting story that occurred right up the freeway in Los Angeles.

April 13, 1993 was just like any other day.

That morning, the children at 49th Street School in South Central, Los Angeles woke up, grabbed their bags, waved good-bye to their parents, and made their way to school. Twenty minutes before the school bell rang, you could feel the promise of youth and hear the laughter of children in the air.

All except for one small boy.

Ten year-old Jorge stood at the school entrance crying. He reached into his backpack, slowly pulled out the gun he had taken from his parents' bedroom, placed the gun against his temple and fired.

One bullet was all it took. With one shot, Jorge ended his short life and sent shock waves of grief and confusion throughout his community -- as parents, students, and teachers tried to explain the inexplicable.

"Why?" they asked. "Why would a ten year-old boy have a gun? And why in the world would he take his own life?"

Tragically, such questions have become far too common.

Every day in this country, about fifteen children die in gun-related accidents, suicides, and homicides. And the problems that children and teenagers are facing go far beyond violence.

Every day, approximately 25 young people are infected with HIV, more than 1,000 young people give birth out-of-wedlock, more than 3,000 young people

start smoking, and more than 1.2 million young people have at least five alcoholic drinks.

And then there's the resurgence of marijuana among 12 to 17 year olds -- the monthly usage rate has nearly doubled since 1992.

Make no mistake, if we don't act fast, we could lose an entire generation of young people.

That was the key message of the major report, "Great Transitions: Preparing Adolescents for a New Century," released by the Carnegie Corporation of New York two weeks ago. The report finds that at least one-half of our teenagers are at risk for dangerous behaviors that could seriously diminish their lives. We're talking about millions and millions of young people.

Maybe they'll light up that first cigarette, and start a slow-burning fire in their lungs. Maybe they'll learn the hard way that you don't handle drugs -- drugs handle you. Maybe they'll make a rash decision -- every parent's nightmare -- like driving while drunk or getting in a fight when they should have walked away.

These aren't somebody else's children, and this isn't somebody else's worry. This is a major public health issue -- an American problem that touches the lives of each and every family -- regardless of race, religion, region, and economic background.

But don't take my word that something must be done. Let's hear it first-hand, from young people themselves:

A 16 year-old girl says: "I'd like to be a model. Smoking burns off a lot of calories."

A college sophomore says: "I'm not even a heavy drinker, except every time I drink, I get drunk."

A high school freshman says, "I like violence. I like seeing violence. I just really like watching violence" -- especially video games.

And then there's a 16 year-old boy dealing drugs in New York City. He says, "My father would always say 'Stay in school. Don't drop out. Don't drink or do drugs.' But he never did anything about it himself, so what's the use?"

What's the use?

In the mouths of our teens, those may be the three saddest words in the English language.

What's they use?

They speak of emptiness in what should be a time of exploration. They speak of resignation in what should be a period of wonder. They speak of a hopelessness that makes people numb to all they are and can be.

Why do young Americans who are for many years on the right track end up veering off course and diminishing their lives?

Lots of reasons.

Part of it is poverty and the lack of opportunity -- primary indicators of a child's future health and future life chances in this country. As Marian Wright Edelman likes to say, "opportunity is the best contraceptive."

Part of it is the dangerous messages some parts of our culture send to the young, messages like:

"Smoking is glamorous."

"Marijuana is cool."

"Everybody's having sex."

"A gun gets you respect."

Part of it is that we who are public health leaders have to do a better job educating and inspiring each new generation to live healthy lives: We can never give up.

But critically important is something else:

I have a teenage advisory group -- 17 young people from all walks of life who meet with me about once a month. Whether we're talking about preventing drug use or depression, smoking or sex, they consistently say the same thing: They say that parents are by far the most influential people in their lives. They say that parents and families can do the most to save them. And -- despite the aura of independence that teenagers project so well -- they say that most young people need and want the everyday love, attention, involvement, and, yes, discipline of their parents.

There's a beautiful passage about parenting and communication in a new book called The Air Down Here, written by a 16 year-old young man in the Bronx named Gil Alicea. Gil writes: "My dad doesn't keep secrets from me 'cause he loves me too much. He doesn't keep secrets from me 'cause he doesn't want me to keep secrets from him Even if it's something bad, he just wants me to tell the truth"

We all know that Gil and my teenage advisors are right -- the family is the core institution in this country -- and yet somehow we have evolved into a society in which a gauntlet of factors keep mothers and fathers from raising their children the way they would like.

Parents are working longer hours with less job security. They have less time to spend with their children. They're finding it harder to pay today's grocery bills while saving for tomorrow's college bills.

There are more families in which both parents are working. There are more single-parent families. There are more parents who walk away from the children they created. There are fewer families that feel connected to strong, supportive communities. And there is more competition for their children's attention.

So there you have it: It has become harder and harder for parents to raise their children -- at the precise moment when children need their parents -- and other caring adults -- more than ever.

No wonder so many parents are terrified.

One mother in suburban Virginia put it best when she said, "I went from wanting my son to win the Nobel Prize to wanting him to survive."

As a society, we have to lock arms to help that mother and all parents, and that means -- first and foremost -- we have to stop those self-proclaimed revolutionaries on Capitol Hill from implementing a budget that would burn holes in our public health system and harm every single family in America.

Consider their radical plans to slash Medicare and hammer Medicaid -- changes that would eliminate coverage for as many as 4.4 million children nationwide in 2002.

How does that help families?

Consider their radical plans to slam the door on 1 million women and 74,000 newborns per year who depend on Healthy Start infant mortality prevention services.

How does that help families?

Consider their radical plans to roll back the Earned Income Tax Credit -- which means that the working families of 23 million children will have their taxes raised by an average of \$415 in 2002.

Tax increases for people who play by the rules How does that help families?

Consider the radical House plan to say that no teenager under 18 will ever again receive welfare if they have a child.

How does that help families?

Consider their radical plans to gut education, drug prevention, and summer jobs for teenagers -- all commonsense efforts to prevent the galaxy of risky behaviors that leave parents lying awake at night.

How does that help families?

These radicals care more about protecting uzis than school lunches.

They care more about tearing down speed limit signs than putting up decent housing.

They care more about lavish tax breaks for the few than health security for all.

They think summer jobs are pork and tobacco is a vegetable.

They think environmental justice means an equal opportunity to pollute.

They're giving up on children, teenagers, and parents exactly when they need us the most.

That reminds me of the old saying that the only difference between genius and stupidity is that genius has its limits.

The President has laid down his marker.

He has promised to send their budget right back where it came from with a big fat veto -- unless they come back with a plan to balance the budget the right way -- by protecting families, protecting our health system, and protecting the principle of the "common good" that has held our country together for 219 years.

We do need change We do need more flexibility to integrate our health and social service programs.

I'd like you to think with me about a new public health strategy -- a new youth development strategy -- a comprehensive, collaborative approach that I call, "Safe Passages."

Safe Passages means working in partnership with all the different adults and institutions in young people's lives -- to help them steer their precious young people through the sometimes rocky waters of adolescence.

This is not the old top-down, heavy-handed, overly programmatic approach to solving problems.

Instead, we need to define our role more clearly -- to serve as the glue that holds together our various partners and fills gaps that would become gaping holes without state-federal- community partnerships.

So what does Safe Passages mean specifically?

It means increasing our capacity to support major research on all aspects of adolescent health and development -- everything from the needs of vulnerable populations to how much unsupervised time kids have and what they do with it.

It means moving away from the old "model program" approach to federal grants -- where we tell communities what they need. Instead, we're using federal, state and private resources to catalyze community coalitions to develop comprehensive plans for youth development -- plans that understand that teenage drug use, violence, sexual activity, and other problems are related to one another, and to overarching social problems like poverty and racism.

It means sponsoring major new national health campaigns in areas like AIDS prevention and the nutrition food labels -- to empower children and teenagers and their parents with critical information needed to choose healthy lives.

It means getting into teenage communication networks.

You know, I come from a Washington world in which people honestly believe that the only way to communicate with the American public is through brochures and posters.

But you all know that the brochure approach to public health communications is a relic from a bygone era. Most teenagers don't spend five minutes per year reading brochures.

What they do is absorb popular culture by the ton.

They rent videos. They play interactive video games. They log on to the Internet. They watch TV -- no, they interact with TV -- channel surfing through cable stations at the speed of sound; shouting back at the television; tuning into talk shows in which the audience is as important as the guests; and continuously incorporating popular culture into their own speech and their own thinking.

I do believe that groups like the Ad Council and the Partnership for a Drug Free America do get it: Their public service announcements always seem to keep up with where kids are -- but that's just one piece of what's needed. We need to bring public health communications into the 21st century -- and into our teenagers' heads and hearts.

And the first step is to candidly admit that we health experts can't do this alone and certainly shouldn't try.

That's why, as a part of Safe Passages, we're teaming up with leaders throughout the media and entertainment industries -- from daytime talk show hosts to TV scriptwriters to the editors of all the popular magazines.

As public health leaders, we need to challenge and cajole and ultimately help the media industries to use their enormous access into American homes to promote real dialogue between parents and teenagers, and to get rid of the mixed messages that cause so much confusion to families around the kitchen table.

This is the future of public health communications in this country: getting on board the information superhighway to transport our young people to safe passage.

Perhaps the administration effort that most clearly reflects our Safe Passages strategy is the children's tobacco initiative, which is ultimately about giving power back to parents.

As we were developing our proposal, some people said we can't afford to incur the wrath of a Goliath-like power like the tobacco industry.

We said, we can't afford not to.

There are more than 400,000 tobacco-related deaths per year in this country -- and the vast majority of those people began smoking regularly in their teens -- or younger.

The tobacco culture has essentially functioned as a "third parent" for American children -- enticing them with attractive images; playing upon their desire to be glamorous; alluring them with T-shirts and trinkets; and giving them easy ways to obtain cigarettes from vending machines, the mail, and even free give-aways.

There's not a parent in this country who wants their children to endure the suffocating death grip of emphysema or lung cancer.

That's why we have proposed both to limit the access and the appeal of tobacco products to children under age 18 with what are -- I believe -- some of the boldest public health proposals this country has ever seen.

Some might say, "Can't parents take care of their children?"

The answer is, of course they can.

That's precisely the point of our proposal -- to make sure that parents -- not the tobacco culture -- are in control when it comes to educating children about an addiction that could take years off their lives. That's why we must all stand with parents and say, "Yes, we will help you protect your child. Yes, we will put your interests before the special interests" -- and not just with tobacco.

We are a safer country because of the Brady Handgun Law and the assault weapons ban. We are a healthier country because we didn't let the extreme right abolish family planning services under Title X. And we will be a wiser country when parents are able to take advantage of the new V-chip technology -- which this administration strongly supports -- to control the level of violence that their children are exposed to on TV.

Time and time again, this administration has taken on the tough issues and the powerful special interests because that's what good for parents and their children.

That's the right role for the federal government, the national government, the people's government -- in partnership with states, counties, cities, communities, schools, universities, and parents.

The fact is, government alone can't solve the galaxy of health problems our children face.

The real passports to safe passage must come from people who share the everyday worlds of our children and teenagers --primarily parents -- but also other caring adults: grandparents, older siblings, teachers, coaches, counselors, clergy, caregivers, employers, media figures, community leaders, and, of course, young people themselves.

And we all must testify.

We all must preach a pro-youth message from our own personal bully pulpits:

A message that inspires our communities to create the presence of opportunity for young people -- strong schools, meaningful jobs, safe streets, and real opportunities to serve.

... And a message that shows young people how much we value them and want to hear their views.

No audience is too small. No pulpit is too close to the ground. And no voice can ever be too soft to save a life.

As healers and educators and public health leaders, you have a special role to play.

You see the human face of public health tragedies like AIDS, violence and substance abuse. You know the complexity of teenage life. You know the importance of prevention. You know the value of comprehensive, community-based solutions. And you know that the imperative of reaching kids early -- gaining their trust -- giving them our ears -- getting our arms around them -- and never letting go.

We need your leadership as part of a national crusade on behalf of our youth -- one that goes community by community, block by block, home by home -- making sure that children and teens become hooked on hope and too strong for wrong.

And why should we make this crusade?

It is the simple fact that -- anywhere you look in this country -- west of the Mississippi or east, south of the Mason-Dixon line or north -- what you find is an enormous reservoir of great young people ... national treasures, not an alien nation, and they're doing great things.

I'm talking about 15 Girl Scouts in Greensboro, North Carolina who raised \$40,000 last year and used it to build a house for Habitat for Humanity.

I'm talking about a Louisiana group called Teens for Life that is canvassing the state to provide AIDS prevention and counseling to their peers.

I'm talking about some New York City teenagers -- volunteers in the President's AmeriCorps program -- who produce their own documentaries on topics like pollution, discrimination, and domestic violence.

And I'm talking about millions of young Americans who show quiet courage and commitment every day of their lives:

Doing their homework in the library after a gruelling soccer practice; going right from an 8-hour school day to violin practice or a part-time job; helping out their parents by looking after younger sisters and brothers; and, above all, living their lives with passion and intensity and enormous energy.

They are our national future -- our national present -- and the reason we must put our heart and souls in motion to assure safe passages for all. Thank you.



DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary

Office of Public Health and Science
Office of International and Refugee Health

Memorandum

July 5, 1996

To: International Health Representatives

From: Director
Office of International and Refugee Health

Subject: Calendar of Events

I want to share with you the attached calendar of events for the balance of the year, and including some events scheduled for 1997 and 1998. If you believe there are other events, which should be added to the calendar, please do let us know. (Amal Thomas - FAX 301 443-6288).

A handwritten signature in cursive script, appearing to read "Linda", is positioned above the printed name.

Linda A. Vogel

Attachment

INTERNATIONAL HEALTH CALENDAR

July 1996 onward

Compiled by Office of International and Refugee Health, OPHS/OS
(Updated 7/5/96)

July 1996

- | | |
|------------|--|
| July 1-2 | First Planning Council meeting for Binational Tuberculosis Campaign
Saltillo, Mexico |
| July 7-12 | XIth International Conference on AIDS
Vancouver, B.C., Canada |
| Jul 8-11 | Indo-U.S. Vaccine Action Program JWG Meeting
Bethesda, MD
OIRH staffing; NIAID & FIC/NIH, CDC, FDA participating. U.S. chair - Dr. Frederick Robbins, Case Western Reserve |
| July 8-9 | Interagency Coordinating Committee on U.S.-Mexico Border Health meets in El Paso
Note: The binational forum to address Border XXI environmental health objectives
(Dick Walling participating) |
| July 12 | Gore-Chernomyrdin Health Committee Meeting
Moscow
(Secretary, Dr. Boufford, Dr. Gaus, HCFA Participating) |
| July 13 | Gore-Chernomyrdin Health Committee, Health Policy Roundtable
Moscow
(Secretary Co-chairing) |
| July 15-16 | 7th Gore-Chernomyrdin Commission Meeting
Moscow
(Secretary Participating) |
| July 17-18 | Visit of German Federal Minister for Family Affairs, Senior Citizens, Women and Youth, Claudia Nolte, to Washington, D.C.
Will meet with Secretary, Elaine Johnson, SAMHSA and Peter Edelman, OS |
| July 22 | Gore-Mbeki Meeting |

July 27-28 U.S.-Japan Conference on Emerging Diseases
Kyoto, Japan
(Organized by NIAID)

July 29-30 Planning Meeting on U.S.-Japan Common Agenda
Emerging and Reemerging Diseases Area
Tokyo, Japan

August

Aug. 8-10 U.S.-Canada Women's Health Forum
Ottawa, Canada

Aug. 8-9 Third Meeting on Children and Social Policy
in the Americas
Santiago, Chile
(Departmental participant to be determined)

September

FGM roundtable - dates not determined

Sept. 5-7 International Research Conference on Ebola
and Other Filoviruses
Antwerp
OIRH co-sponsor with FIC/NIH (organizer)

Sept. 9-13 WHO Western Pacific Regional Committee
Meeting
Seoul, Republic of Korea
(Dr. Bart to participate)

Sept. 18-21 Third Annual Hemispheric Health Ministers'
Conference
Miami

Sept. 23-27 PAHO Directing Council Meeting
Washington, D.C.
(HHS participating)

Sept. 27-28 PAHO Executive Board Meeting
Washington, D.C.
(Dr. Boufford, Mrs. Vogel, others
participating)

October

TBD Reproductive Health Meeting in Bellagio
Dr. Lee

TBD Canadian Medical Research Council Meeting
Dr. Lee, Dr. Wendy Baldwin, NIH

TBD Secretary visits South Africa

November

Nov. 13-17 World Food Summit, Rome
(FDA lead for HHS)

Nov. 17-21 American Public Health Association
New York City

December

Nov. 28-29 WHO Executive Board Subgroup on Health
Systems
Geneva
(Dr. Boufford)

Dec. 2-3 WHO Executive Board Subgroup on
Administration and Finance
(Dr. Boufford)

Dec. 4-6 WHO Task Force on Health and Development
Geneva
(Dr. Boufford)

1997

January:

Jan. 20-31 WHO Executive Board Meeting

May:

May 5-16 World Health Assembly, Geneva

May 19-20 WHO Executive Board Meeting

June:

June 4-6 U.S.-Mexico Border Health Association meeting
Phoenix, Arizona


September:

Sept. 14-18 1997 International Health Congress
State of Maryland and WHO
Baltimore

1998

December

TBD Second International Conference on Health
Policy and Health Services Research
Israel

FACSIMILE TRANSMISSION SHEET**FROM: LINDA A. VOGEL****Director
Office of International and
Refugee Health****Department of Health and Human Services
5600 Fishers Lane
Rockville, Md. 20857
RM.18-75****TEL: 301-443-1774
FAX: 301-443-6288****E-Mail: LVOGEL@OSOPHS
Internet: LVOGEL@OSOPHS.SSW.DHHS.GOV****OFFICE OF INTERNATIONAL AND REFUGEE HEALTH****TO: Ms. Lahoma Romacki FAX NUMBER: 202-632-1096****DATE: 8/6/96 NUMBER OF PAGES: 3
(INCLUDING COVER SHEET)**☐ FYI
☐ AS REQUESTED☐ FY ACTION
☐ AS DISCUSSED**MESSAGE:**



DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary

Office of Public Health and Science
Office of International and Refugee Health

August 6, 1996

Memorandum

To: Addressees

From: Director
Office of International and Refugee Health

Subject: International Health Representatives Meeting - **August 8, 1996**

This is to confirm that the PHS International Health Representatives' Meeting will be held on Thursday, **August 8, 1996**, from 2-4 p.m. in **the Parklawn Building, Room 17-09.**

The preliminary agenda is as follows:

Introduction of Associate Director for Refugee Health, OIRH

Reports on/status of:

- ◆ Gore-Chernomyrdin Health Committee Meeting
- ◆ Emerging and Reemerging Disease Initiatives
 - U.S.-EU Transatlantic Alliance
 - U.S.-Japan Common Agenda
- ◆ U.S.-Mexico Binational Commission
- ◆ Gore-Mbeke S&T Committee - Health Issues
- ◆ U.S.-India Cooperation

Agency Reports/Highlights


Other

- FGM Workshop

A handwritten signature in cursive script, reading "Linda A. Vogel".
Linda A. Vogel

Addressees

Dr. Jo Ivey Boufford, PDASH
Mr. Norman Prince, PSC
Mrs. Barbara Cohen, OPA/OPHS
Dr. Susan Blumenthal, OWH/OPHS
Mr. Bruce Chelikowsky, IHS
Dr. Mary Cummings, AHCPR
Dr. Melinda Moore, CDC
Mr. George Dines, HRSA
Dr. Philip Schambra, NIH
Ms. Linda Staheli, NIH
Ms. Georgia Buggs, OMH/OPHS
Mr. Stephen Sawmelle, SAMHSA
Ms. Sharon Smith Holston, FDA
Dr. Stuart Nightingale, FDA
Mr. Walter Batts, FDA
RADM Beth Mazella, OCN
Dr. Linda Myers, ODPHP/OPHS
Ms. Ellen Shippy, DOS/STH
Mr. Anthony Rock, DOS/STH
Dr. Jonathan Davis, DOS/STH
Ms. Nancy Carter-Foster, DOS/STH
Mr. Ronald Lorton, DOS/SCP
Mr. Joseph Baldi, HRSA
Ms. Lahoma Romacki, NACO
Dr. Francis Notzon, NCHS
Mr. David Hohman, OS
Mr. David Oot, AID
Dr. Eric Goosby, AIDS/OHAP
Dr. Elaine Daniels, AIDS/OHAP
Dr. Juan Ramos, NIMH/NIH
Dr. Faye Calhoun, NIAAA/NIH
Dr. Pat Needle, NIDA
Ms. Carol Dabbs, USAID
Dr. Noreen Hynes Carus, Peace Corps
RADM Stephen Corbin, OSG
Dr. Robert Knouss, OEP
OIH Staff - AID and Parklawn

FACSIMILE TRANSMISSION SHEET**FROM: LINDA A. VOGEL****Director
Office of International and
Refugee Health****Department of Health and Human Services
5600 Fishers Lane
Rockville, Md. 20857
RM.18-75****TEL: 301-443-1774
FAX: 301-443-6288****E-Mail: LVOGEL@OSOPHS
Internet: LVOGEL@OSOPHS.SSW.DHHS.GOV****OFFICE OF INTERNATIONAL AND REFUGEE HEALTH****TO: Ms. Lahoma Romacki** **FAX NUMBER: 202-632-1096****DATE: 9/11/96** **NUMBER OF PAGES: 2**
(INCLUDING COVER SHEET)☐ **FYI**
☐ **AS REQUESTED**☐ **FY ACTION**
☐ **AS DISCUSSED****MESSAGE:**

• NCIH

• NORA ltr.

W. L. supposed to be responding

Page 2

Addressees

Dr. Jo Ivey Boufford, PDASH
Mr. Norman Prince, PSC
Mrs. Barbara Cohen, OPA/OPHS
Dr. Susan Blumenthal, OWH/OPHS
Mr. Bruce Chelikowsky, IHS
Dr. Mary Cummings, AHCPR
Dr. Melinda Moore, CDC
Mr. George Dines, HRSA
Dr. Philip Schambra, NIH
Ms. Linda Staheli, NIH
Ms. Georgia Buggs, OMH/OPHS
Mr. Stephen Sawmelle, SAMHSA
Ms. Sharon Smith Holston, FDA
Dr. Stuart Nightingale, FDA
Mr. Walter Batts, FDA
RADM Beth Mazella, OCN
Dr. Linda Myers, ODPHP/OPHS
Ms. Ellen Shippy, DOS/STH
Mr. Anthony Rock, DOS/STH
Dr. Jonathan Davis, DOS/STH
Ms. Nancy Carter-Foster, DOS/STH
Mr. Ronald Lorton, DOS/SCP
Mr. Joseph Baldi, HRSA
Ms. Lahoma Romacki, NACO
Dr. Francis Notzon, NCHS
Mr. David Hohman, OS
Mr. David Oot, AID
Dr. Eric Goosby, AIDS/OHAP
Dr. Elaine Daniels, AIDS/OHAP
Dr. Juan Ramos, NIMH/NIH
Dr. Faye Calhoun, NIAAA/NIH
Dr. Pat Needle, NIDA
Ms. Carol Dabbs, USAID
Dr. Noreen Hynes Carus, Peace Corps
RADM Stephen Corbin, OSG
Dr. Robert Knouss, OEP
OIH Staff - AID and Parklawn



DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary

Office of Public Health and Science
Office of International and Refugee Health

September 10, 1996

Memorandum

To: Addressees

From: Director
Office of International and Refugee Health

Subject: International Health Representatives Meeting - **September 12, 1996**

This is to confirm that the PHS International Health Representatives' Meeting will be held on Thursday, **September 12, 1996**, from 2-4 p.m. in **the Parklawn Building, Room 17-05**.

The preliminary agenda is as follows:

Guest Speakers

Mr. John Hounsell
National Technical Information Service
Video and other communication resources of NTIS


Dr. Michael Linnan
HHH Representative in Vietnam


Program Updates

- India-Extension of USIF
- Russia
- FGM Workshop

Agency Reports/Highlights

Other


Linda A. Vogel

FACSIMILE TRANSMISSION SHEET**FROM: LINDA A. VOGEL****Director
Office of International and
Refugee Health****Department of Health and Human Services
5600 Fishers Lane
Rockville, Md. 20857
RM.18-75****TEL: 301-443-1774****FAX: 301-443-8288****E-Mail: LVOGEL.OSOPHS****Internet: LVOGEL@OSOPHS.SSW.DHHS.GOV****OFFICE OF INTERNATIONAL AND REFUGEE HEALTH**

TO: Ms. Lahoma Romacki **FAX NUMBER: 202-632-1096****DATE: 12-9-96** **NUMBER OF PAGES: 3**
(INCLUDING COVER SHEET)☐ FYI
☐ AS REQUESTED☐ FY ACTION
☐ AS DISCUSSED**MESSAGE:**



DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary

Office of Public Health and Science
Office of International and Refugee Health

December 9, 1996

Memorandum

To: Addressees

From: Acting Director
Office of International and Refugee Health

Subject: Cancellation of International Health Representatives
Meeting - **December 12, 1996**

This is to advise that the PHS International Health Representatives' Meeting will be not be held on Thursday, **December 12, 1996**, from 2-4 p.m. in **the Parklawn Building, Room 17-05**.

The next meeting is tentatively scheduled for January 9, 1997.

Roscoe M. Moore, Jr., D.V.M., Ph.D., D.Sc.

age 2 -

Addressees

Dr. Jo Ivey Boufford, PDASH -
Mr. Norman Prince, PSC
Mrs. Barbara Cohen, OPA/OPHS
Dr. Susan Blumenthal, OWH/OPHS
Mr. Bruce Chelikowsky, IHS
Dr. Mary Cummings, AHCPR
Dr. Melinda Moore, CDC
Mr. George Dines, HRSA
Dr. Philip Schambra, NIH
Ms. Linda Staheli, NIH
Ms. Georgia Buggs, OMH/OPHS
Mr. Stephen Sawmelle, SAMHSA
Dr. Stuart Nightingale, FDA
Mr. Walter Batts, FDA
RADM Beth Mazella, OCN
Dr. Linda Myers, ODPHP/OPHS
Ms. Ellen Shippy, DOS/STH
Dr. Jonathan Davis, DOS/STH
Ms. Nancy Carter-Foster, DOS/STH
Mr. Ronald Lorton, DOS/SCP
Mr. Joseph Baldi, HRSA
Ms. Lahoma Romacki, NACO
Dr. Francis Notzon, NCHS
Mr. David Hohman, OS
Mr. David Oot, AID
Dr. Eric Goosby, AIDS/OHAP
Dr. Elaine Daniels, AIDS/OHAP
Dr. Juan Ramos, NIMH/NIH
Dr. Faye Calhoun, NIAAAA/NIH
Dr. Pat Needle, NIDA
Ms. Carol Dabbs, USAID
Dr. Noreen Hynes Carus, Peace Corps
RADM Stephen Corbin, OSG
Dr. Robert Knouss, OEP
Ms. Jocelyn Mendelsohn, OGC
OIH Staff - AID and Parklawn

Office of International Affairs



Patsy

Department of Health and Human Services

Room 639-H, HHH Building

200 Independence Avenue, S.W.

Washington, D.C. 20201

Telephone: 202-690-6174

Fax: 202-690-7127

Internet: DHOHMAN@OS.DHHS.GOV

Date: 7/2

To: Lahoma Organization: _____

Telephone: _____ Fax: _____ Number of pages: 4

From: **David E. Hohman**
Director, OIA

MESSAGE:

Per conversation - pls see this by Patsy
& Richard for substance, not
minor edits. Thanks.

Need ASAP

DRAFT 11H00, July 2, 1996

**Joint Declaration of the Minister of Health of Canada,
the Secretary of Health the United States of Mexico
and the Secretary of Health and Human Services, the
United States of America**

**Trinational Satellite Symposia, The XIth International
Conference on AIDS**

**July 9, 1996
Vancouver, Canada**

**HIV affects not only the individual with the disease, but
also causes profound stress for families, caregivers
and communities. Today, we are acknowledging those
who support persons living with HIV or AIDS, "as a
shared priority of our nations".**

*especially
families*

**In this era where more citizens, their families and
communities are being affected by HIV infection and
AIDS, we acknowledge our support for the quality of
life for persons living with HIV infection or AIDS and
those who support them, including their families,
caregivers, and communities.**

Care for

- 2 -

The governments of our countries can facilitate change and improvement by working collaboratively with other levels of government, national organizations, and people living with HIV or AIDS and their organizations to address concerns related to the availability of supportive social environments, adequate and appropriate health and social services, as well as, the development of support systems and networks.

During the coming years, our governments will learn from each other's successes and challenges. Specifically, we will work together to:

- **share experience gained within each country,**
- **share information on innovative approaches, new initiatives, and best practices among countries and**
- **increase collaboration in our HIV/AIDS efforts.**

Signed at the Trinational Satellite Symposia of the XIth International Conference on AIDS, Vancouver '96, in Vancouver, Canada on July 9, 1996.

The Hon. David Dingwall
Minister of Health
Canada

Dr. Juan Ramón de la Fuente Ramírez
Secretary of Health
The United States of México

E.
The Hon. Donna Shalala
Secretary of Health and Human Services
The United States of America

-3-

**Statement of Ministers and Secretary for Press
Announcement**

Our three nations recognize that HIV profoundly affects individuals, their families, caregivers and communities. Today, we are acknowledging those who support HIV affected persons as a shared priority of our nations. We pledge to learn from our individual efforts in our fight against HIV/AIDS and to increase our collaboration to improve quality of life for HIV-affected individuals and their families.